|
|
||||||||
Institut National de la Santé et de la Recherche Médicale U-99 Hôpital Henri Mondor, F-94010 Créteil, France
| |
ABSTRACT |
|---|
|
|
|---|
The present review focuses on the potential physiological regulations involving different isoforms of adenylyl cyclase (AC), the enzymatic activity responsible for the synthesis of cAMP from ATP. Depending on the properties and the relative level of the isoforms expressed in a tissue or a cell type at a specific time, extracellular signals received by the G protein-coupled receptors can be differently integrated. We report here on various aspects of such regulations, emphasizing the role of Ca2+/calmodulin in activating AC1 and AC8 in the central nervous system, the potential inhibitory effect of Ca2+ on AC5 and AC6, and the changes in the expression pattern of the isoforms during development. A particular emphasis is given to the role of cAMP during drug dependence. Present experimental limitations are also underlined (pitfalls in the interpretation of cellular transfection, scarcity of the invalidation models, and so on).
adenylyl cyclase; calcium; calmodulin; kidney; heart; brain; spermatozoa; opiates; cannabis
| |
INTRODUCTION |
|---|
|
|
|---|
FORTY YEARS AFTER ITS DISCOVERY by Earl Sutherland, cAMP is still the archetypal "second messenger." But the cAMP signaling pathway, once considered to be simple and straightforward, has become very complex indeed. One reason is the fact that cAMP is acting not only by promoting protein phosphorylation via activation of protein kinase [protein kinase A (PKA)] but also by inducing protein-protein interaction independently of any phosphorylation (38, 81). Another reason is the extreme variety of potential regulations of cAMP synthesis and degradation, due to the multiplicity of phosphodiesterases (up to 40) and adenylyl cyclase (AC) isoforms.
The present review deals with the latter enzymes that convert ATP into
cAMP. Today, at least nine closely related isoforms of AC, AC1-AC9, and
two splice variants of AC8, have been cloned and characterized in
mammals (63, 75, 145,
152). All of them share a large sequence homology in the
primary structure of their catalytic site and the same predicted
three-dimensional structure. Each of them consists of two hydrophobic
domains (with 6 transmembrane spans) and of two cytoplasmic domains,
resulting in a pseudosymmetrical protein. Only the cytoplasmic domains
(C1 and C2), which constitute the catalytic site, are subject to
intracellular regulations specific for each subtype. In particular the
catalytic activity, as well as the sites for interaction with forskolin and Gs
, requires both cytoplasmic moieties. Elucidation
of the structure-function relationship of ACs has markedly progressed over the last three years due to a series of recent studies, including crystallography and site-directed mutagenesis. The reader is referred to more detailed recent reviews dealing with those aspects
(69, 158, 165).
The distinct properties of the individual isoforms allow them to play an interpretative role in signal transduction instead of being a linear pathway for the activity of the G protein-coupled receptors. Thus, depending on the properties and the relative level of the isoforms expressed in a tissue or a cell type, extracellular signals received by the G protein-coupled receptors can be differently integrated.
The present text will focus on the potential physiological regulations involving the different isoforms. Ideally, one should one day be able to correlate the existence of a specific AC isoform in a given tissue or cell with a specific function or "raison d'être." We are far from it at present and, if we want to avoid tedious phenomenological listings and descriptions, we can only grope for a few well-defined and physiologically relevant systems.
As is usual when commuting between analytic biochemical data and complex signaling networks, one is faced by many potential pitfalls. It is well known, for example, that 1) overexpressing a protein in a cell culture system can greatly alter the stoichiometry of the components of the network and lead to spurious results; 2) a well-defined regulation in vitro may be lost in vivo into a complex and redundant integrated system, (however, this specific regulation may show up in a pathological state); 3) some technical approaches may be too sensitive (e.g., the PCR reaction) or too unsatisfactory (we are still lacking good specific antibodies for all the AC isoforms) to provide unambiguous data; and 4) the probable marked differences in the specific activity of the various isoforms add a further degree of complexity when one analyzes the results of transfection experiments. This has been studied in the case of AC2 vs. AC6 (129), but most likely applies to most isoforms.
It is, therefore, with those caveats in mind that we present here a "progress report" on the cell- and isoform-specific regulations of cAMP synthesis.
| |
TISSUE SPECIFICITY OF mRNA EXPRESSION |
|---|
|
|
|---|
Because of the unavailability of satisfactory antibodies for most
of the isoforms, the tissue distribution has generally been determined
by mRNA studies. Table 1 shows that,
among the large diversity of the AC isoforms, some are widely
expressed, such as AC2, AC4, and AC6, whereas others are more
specifically expressed, for example AC1 in tissues of neural origin and
AC5 in heart and striatum. Although mRNA for the various AC isoforms
was found in brain, their expression is restricted to discrete
structures of the central nervous system as demonstrated by in situ
hybridization (cf. Table 1). This is particularly clear for the
Ca2+/calmodulin-stimulated isoforms, AC1, AC3, and AC8. AC1
is abundant in the dentate gyrus of the hippocampus and the cerebral
cortex (189), the highest expression of AC3 is exhibited
in the olfactory neuroepithelium (188), whereas the
important area for AC8 expression is the hypothalamus (16,
102), where it is the only
Ca2+/calmodulin-stimulated isoform (110,
187, 188). In chick heart, AC5 is essentially
expressed in myocytes, whereas AC6 is expressed in nonmyocyte cells
(198). Moreover, the colocalization of the L-type Ca2+ channels with different elements of
the cAMP-mediated signaling pathway, including AC in cardiomyocytes
along the T tubule membranes (56), will provide new
insights for understanding of the regulation of this pathway.
|
The cellular heterogeneity of most of the tissues studied does not allow one to determine precisely in which type of cell from a given tissue a specific cyclase isoform is expressed, with the notable exception of kidney (18). At least five AC isoforms are expressed in rat kidney, AC6, AC5, AC4, AC7, and AC9, as found out by Northern blot (143, 179). The expression of AC4, AC5, and AC6 has been determined along the nephron. The pattern of distribution of AC6 suggests a greater concentration in the medulla than in the cortex. At the cellular level, this distribution is characterized by a widespread presence along the whole renal tubule. AC6 is more abundant in the distal segments (in the collecting tubule and in the thick ascending limb), whereas AC5 expression is restricted to the glomerulus and to the initial portions of the collecting duct, and AC4 only in the glomerulus (18). These observations raise the important questions as to whether more than one isoform can be expressed in one cell type and how it can be targeted within the cell compartments. Through the assay of hormone-dependent cAMP levels and on the basis of the properties of Ca2+-inhibitable AC isoforms, Chabardes et al. (18) proposed that "AC5 is mainly, if not exclusively, expressed in the glucagon-sensitive cells and that AC6 is present in the vasopressin-sensitive cells of the outer medullary collecting duct of the rat kidney." The functional relevance of AC localizations in the kidney will be described later.
| |
TRANSCRIPTIONAL REGULATION OF AC GENES |
|---|
|
|
|---|
Whereas chromosomal localization of each of the nine isoforms has
been determined both in human and in mouse (49,
60, 61, 66, 134,
150, 173) (Table
2), little is known concerning the
promoter and the structure of the genes. Part of the promoter regions
for AC3 and AC8 has been described with potential sequences for binding
specific factors (115, 178). Moreover,
215,441 kb of the human chromosome 16p13.3 have been sequenced (GenBank
accession no. AC005736), which should cover the complete AC9 gene. The AC9 gene extends over >150 kb and 9 introns.
|
AC3 was initially identified as the specific isoform of the olfactory
neuroepithelium (10, 188). Several proteins
of the olfactory signaling pathway, including the putative odorant
receptor, G
olf, AC3, and the olfactory nucleotide-gated
channel, have been identified and localized in the cilia by
immunohistochemichal and electrophysiological methods (78,
107). Wang et al. (178) have identified
binding sites for the olfactory neuron-specific transcription factor
Olf-1 in the sequence surrounding the transcription initiation site of
all these genes. This suggests that, in sensory neurons, the expression
of these genes is coordinated and involves tissue-specific
transcription factors. AC3 has also been found expressed in many other
tissues, including bovine adipose tissue (20,
58), male germ cells (35, 57),
and luteal cells from bovine ovaries (100). Expression of
AC3 mRNA has also been detected in human islets isolated from
nondiabetic individuals (193). Recently, two point
mutations in the promoter region of the AC3 gene have been associated
with a decrease in the glucose-induced insulin release in spontaneously
diabetic rats, possibly through an alteration of AC mRNA transcription
(1). It will be important to determine whether mutations
in the AC3 gene promoter are also present in patients with type 2 diabetes.
The complete structure of the murine AC8 gene has been recently
characterized (115). The AC8 gene extends over 18 exons, which encompass ~200 kb of the mouse genomic DNA. In the 5' end, a
very long untranslated sequence (~2 kb upstream from the translation initiation site) is highly conserved among the different species, i.e.,
mouse, rat, and human (16, 36,
115). This suggests that posttranscriptional regulations
play an important role in the expression and/or localization of AC8. As
for the promoter region of the AC3 gene, the AC8 promoter does not
contain any canonical TATA box but does include a consensus cAMP
response element (CRE). The presence of a putative CRE sequence in the AC8 gene promoter might have some relevance because the induction of
AC8 expression in specific regions of the brain during chronic administration of morphine (87, 103) is
attenuated by injection of a cAMP-responsive element binding protein
(CREB) antisense oligonucleotide (87), and because CREB
(
/
)-mutant mice have reduced morphine abstinence syndrome
(98).
All the sequence data available to date allow only limited conclusions. However, it is noteworthy that the structure of the different AC genes appears to be different: the first exon of AC3 is not translated (178), and <1 kb of the promoter region is sufficient to control the level of expression of this isoform (1). The mouse AC8 and human AC9 genes have a different exon organization with apparently no conservation of the splice donor sites, whereas some conservation exists between the mouse AC8 gene and the Drosophila melanogaster rutabaga gene (115). Finally, Muglia et al. (115) demonstrated that DNA sequences within the 10 kb preceding the first exon of the AC8 gene are critical for the establishment of region-specific pattern of expression of this isoform.
| |
POTENTIAL REGULATIONS OF MAMMALIAN ACs |
|---|
|
|
|---|
As with most of the proteins involved in signal transduction, the
fact that ACs exist as multiple isoforms with different regulatory
properties (Table 3) allows complex
signal integration, but may also lead to spurious conclusions. In most
of the cases, regulatory properties of the cAMP-synthesizing machinery
have been determined on purified membranes, and it is not clear by which combinatorial process the observed properties are integrated in
the intact cells to produce a specific response to external stimuli. In
some cases, the regulatory properties of individual isoforms have been
determined in stably transfected, intact cells. Although these
conditions permit the integration of informations from multiple
signals, the transfection experiments are generally performed in cell
types with low levels of cyclase activity or in cell types that do not
express the transfected isoform. In those conditions, the physiological
effectors needed for a given isoform may be absent, leading to
nonreproducible data from cell type to cell type. Given the cell
heterogeneity of most of the tissues, and the fact that most of the
cells probably express multiple isoforms of AC, the analysis of the
regulatory properties of one AC in its own context may be an unending
challenge. The renal epithelial cells of the distal portion of the
collecting tubule, where only one isoform, namely AC6, has been
detected, may be an exception.
|
Stimulation by Gs
-Subunit and by Forskolin
is the major mechanism by
which ACs are activated and the cAMP level is elevated. By expressing
AC1, AC2, and AC6 in insect cells, Harry et al. (65)
demonstrated that different ACs have different affinities for
Gs
, which may provide an explanation for the various
responses of different cell types to hormones and neurotransmitters
that elevate cAMP. These differences are abolished in the presence of
100 µM forskolin. This indicates a conserved mechanism by which
forskolin regulates Gs
coupling to the different ACs.
All ACs, with the possible exception of AC9, are activated by the
diterpen forskolin. One major surprise in the elucidation of the
structure of the ACs was the existence of a highly hydrophobic pocket
at the interface of C1a/C2a, where forskolin acts. This pocket is
different in AC9 compared with the other types of mammalian ACs. A
single mutation transforming the Tyr1082
Leu of mouse
AC9 can confer both binding and activation by forskolin
(192). At this position the Drosophila AC9
protein, which is forskolin-sensitive, contains a Leu
(72). Together, forskolin and Gs
contribute
for a higher cyclase activity. Gilman and colleagues (40,
157, 183) have shown that fragments of the
two cytoplasmic domains of mammalian ACs can be synthesized independently as soluble proteins. On their mixture, both
Gs
- and forskolin-stimulated activity can be restored.
Using this system, Dessauer et al. (41) have characterized
the interaction of AC with forskolin and ATP, although each one has its
own binding site. The affinity of forskolin to AC is greatly reduced in
the absence of Gs
(41).
Inhibition of AC Activity by Gi
The complexity of the hormonal control of AC was first evidenced by Rodbell and co-workers (138), who discovered the dual stimulatory and inhibitory G protein (Gi)-regulatory pathways. The inhibitory action of G protein-coupled receptors on AC activity can be blocked by pertussis toxin. Whereas all isoforms of ACs are potentially activated by Gs
-coupled receptors, the inhibition by
Gi
-coupled receptors appears to be isozyme specific; the
-subunit of the Gi protein, Gi
, acts as a
noncompetitive inhibitor of Gs
-stimulated AC5 and AC6
but has no effect on AC2 and AC8 (22, 85,
161, 163). Using a soluble enzyme system
composed of the C1 and C2 domains of AC5 and AC2, the Gilman group
(42) have demonstrated that only the C1 domain of AC5
retains the ability to bind Gi
within a site close to
the active site of the enzyme.
Regulations by the 
-Subunits of the G Proteins

was thought to inhibit AC activity by
chelating and deactivating stimulatory Gs
. The
possibility of specifically expressing individual AC isoforms in
cultured cells has led to a complete reappraisal of this view.
1) G
has no direct effect on the activity of a few
isoforms (AC3, AC8, AC9) (134, 156). 2) G
activates AC2, AC4, and presumably AC7, directly,
but only in the presence of activated Gs
(55, 95, 139, 156).
This was a surprise and has the potential of explaining many aspects of
cross-talk between different receptors (15,
53, 160, 199). For example,
1-adrenergic stimulation of the
Gq
-subunit can lead to an increase in cAMP through the

-complex, thus explaining the convergent action of
Ca2+ and cAMP on the same target. Here again, the presence
of specific isoforms of AC in a given cell will determine which
regulatory pathways might be involved. Alternatively, a hormone or a
neurotransmitter acting via a receptor normally coupled to
Gi could produce a biphasic action on cAMP production
depending on whether Gi
or G
is predominantly influencing the enzyme (124, 125).
3) Finally, G
directly inhibits the calmodulin- or
Gs
-stimulated AC1 activity (156, 162).
In contradiction to previous data (132, 196),
Bayewitch et al. (11, 12) have also shown, by
transient cotransfection into COS-7 cells of AC isoforms and
- and
-heterotrimeric G subunit, that AC5 and AC6 are markedly inhibited
by G
(particularly
1
2), in
conditions where AC2 activity is stimulated. If this were true in a
physiological context, we would have then a new kind of cross-talk
between receptors, whereby a receptor, not coupled to Gi
or to AC, could inhibit the cAMP formation in an unexpected manner if
AC1, AC5, or AC6 was the predominant isoform in a given tissue.
However, whether this observation is physiologically relevant is not
demonstrated at present.
Regulations by Protein Phosphorylation
Modulation of the enzymatic activity by phosphorylation is a common signature of downstream and feedback regulations in the transduction cascades. In this context, phosphorylation of the ACs by PKA provides a means of desensitization at the effector level. The profiles of the regulatory sensitivity of ACs to protein kinases is different according to each subtype. Both AC5 and AC6 are directly phosphorylated, and inhibited, by PKA (24, 74). Phosphorylation by PKA directly inhibits AC5 activity by decreasing the maximal velocity of the enzyme (74). Phosphorylation of AC6 at the level of Ser674 would disrupt the functional Gs
binding site, leading to the inhibition of AC activity (24). This mechanism could
explain the cAMP-dependent desensitization of glucagon stimulation
described several years ago in hepatocytes (133). This
might be particularly important in the heart where AC5 and AC6 are the
most abundant isoforms and where AC activity has to be strictly
controlled. This suggests the presence of a negative feedback loop at
the level of the cyclase itself as a potential mechanism of
desensitization of the cAMP signaling pathway.
Phosphorylation by protein kinase C (PKC) often results from the
activation of Gq and phospholipase C (PLC)-linked
receptors, which in turn leads to mobilization of Ca2+,
synthesis of diacylglycerol, and activation of PKC. On PKC activation, cAMP production within the cells is altered. Phorbol 12-myristate 13-acetate is able to increase AC activity in cells transfected with
AC1, AC2, AC3, AC5, or AC7. Potentiation of AC1 activity by PKC can be
observed only on Ca2+/calmodulin stimulation
(76), whereas inhibition of AC4 activity by PKC-
is not
observed on basal activity but after Gs
stimulation (201). Whether PKC directly modulates AC activity has been
controversial. In insect cells, AC2 activity is clearly activated by
PKC-
, but this activity is lost on membrane solubilization or AC2
purification, although it retains the stimulation by Gs
and forskolin (47). On the other hand, using purified PKC
and AC, Kawabe et al. (80) have demonstrated that PKC-
can directly phosphorylate AC5, leading to a 20-fold increase in AC
activity. Although PKC-
is less potent to activate AC5, the two PKCs
are additive in their capacity to activate AC. Phosphorylation of AC5
by the different PKCs is particularly important in the heart, where
growth factors including insulin are able to regulate cAMP production
and contractility. In vitro, the
- and
-isoforms directly
phosphorylate and activate AC5. Whereas the
-isozyme activates AC5
in a Ca2+-independent manner, the
-isozyme requires
Ca2+. This affords another mechanism for the
Ca2+-mediated regulation of AC5 activity in heart. In cells
expressing AC5, insulin augments cAMP production through
phosphatidylinositol-3,4,5 triphosphate (PIP3) activation
of the PKC-
(79). In the heart, all hormones or growth
factors that activate PI3-kinase, leading to the formation
of PIP3, which activates PKC-
, would be able to control
cAMP production through a direct activation of AC5. All these
observations demonstrate that PKC can alter the ability of the AC
isoforms to integrate signals derived from multiple inputs. ACs
therefore appear to be important targets for direct or PKC-mediated
modulatory effects of Ca2+. The other very important
regulations of AC by Ca2+, either negative or positive, are
dealt with later.
The mechanism by which a cell can integrate multiple signals to
modulate AC activity is well documented in a paper of Marjamaki et al.
(101). AC2, AC3, and AC4 have been transfected in DDT1-MF2 cells which already expressed AC6, AC7, AC8, and AC9. Whereas AC2 and
AC4 exhibit a high amino acid sequence homology, and share most of
their in vitro regulatory properties, they can be submitted to
different hormonal regulations in vivo: in cells transfected with AC2
or AC4,
2-adrenergic receptor (AR) stimulation initiates both positive (through 
) and negative (through Gi)
effects on Gs-stimulated activity; however, PKC blocks the
negative input from the
2-AR in AC2-transfected cells,
whereas it blocks the positive input in AC4-transfected cells
(101). These observations demonstrate the complexity of
integration of multiple signals by ACs. The authors concluded that this
dynamic process is dependent on the enzyme type and the state of
phosphorylation. The ability of the AC to integrate multiple
information certainly plays a key role in the signaling plasticity
observed during a wide range of physiological or pathological processes
and during development.
Regulations by Ca2+
All AC activities are inhibited by high, nonphysiological concentrations of Ca2+ in the submillimolar range, possibly by competition with magnesium. In certain tissues, including the pituitary gland, platelets, and heart, AC activity has been reported to be inhibited by concentrations of Ca2+ in the micromolar range. This appears to be a feature of the two closely related cyclase isoforms, AC5 and AC6, cloned from heart, liver, kidney, striatum, Reuber hepatoma, or NCB-20 cells (30, 31, 111). When expressed in a variety of recipient cells lines, these isoforms are inhibited by micromolar concentrations of Ca2+, and the inhibition is additive to that elicited by receptors acting via Gi
. Whether Ca2+
modulates AC5 and AC6 activities directly or via a
Ca2+-binding protein remains to be determined.
Ca2+/calmodulin activates AC1 and AC8 by direct binding to a putative calmodulin binding site located in a C1b helical region of AC1 (90, 175) or in the C2 region of AC8 (59). The precise activation mechanism is unknown. It has been proposed, on the basis of other Ca2+/calmodulin binding proteins, that calmodulin binding would disrupt an autoinhibitory interaction between the C1b or C2b region and the catalytic core.
Conclusion
It thus appears that 1) the different ACs have different potential regulatory properties, delineated by their primary structure and/or activity in vitro; 2) the same effector can exert positive or negative effects on the various isoforms; 3) according to the specific pattern of protein expression in the different cell types, the same isoform may be regulated differently; and 4) finally, through Ca2+ regulations, the different signaling pathways, using the various G proteins, can talk together to (hopefully) better regulate cell functions. It is clear that the integration of the multiple signals by AC is a dynamic process and that the ability of the different AC types to respond to activated Gs
, Gi
, G
,
Ca2+, and phosphorylation places the enzyme at a central
point for cross-talk between different signaling pathways.
| |
FUNCTIONAL RELEVANCE OF SPECIFIC ISOFORM EXPRESSION |
|---|
|
|
|---|
Is the Inhibition of AC by Micromolar Concentration of Ca2+ Physiologically Relevant?
Heart and kidney are among the major organs in which Ca2+-inhibitable AC isoforms are predominant. However, it is difficult to clearly attribute a physiological role to this specific regulation. We and others have demonstrated that, although the two major isoforms in rat heart, AC5 and AC6, are equivalent at birth, the AC5 mRNA becomes predominant in the adult rat heart (52, 169). Sympathetic stimulation of cardiac tissue elevates cAMP, which in turn leads to an increase in intracellular Ca2+, and the wave of Ca2+ has been proposed to lead to a rhythmic dissipation of the cAMP signal (32). The capacitative entry of Ca2+, secondary to the emptying of intracellular Ca2+ pool (e.g., by the use of the Ca2+-ATPase inhibitor thapsigargin), has been proposed to play a major role in positively (AC1 or AC8) or negatively (AC5 or AC6) regulating AC activity (26, 33). That it is the only mechanism by which a change in cytosolic Ca2+ concentration can influence AC activity is probably still open to question, especially in excitable tissues where the capacitative entry of Ca2+ plays a minor role if any.In fact, the relative effects of Ca2+ and cAMP are much more complex. We have just demonstrated that overexpression of AC8, a neural, Ca2+/calmodulin-stimulatable AC isoform in mice heart (91a) is not only compatible with normal heart function but even leads to enhanced function, with no cardiomegaly or fibrosis in 3-to 5-mo-old animals. If the rhythmic Ca2+ inhibition of cAMP formation were of major importance, we would have expected this transfection to be lethal.
In the kidney, the preferential distribution of AC6 in the medulla
(143) is due to the presence of two segments, collecting tubule and thick ascending limb, in which AC6 is highly expressed (18). An important point is the subcellular location of
the AC in the epithelial cells. It is generally accepted that AC is localized to the basolateral domain (144). However, a
growing body of literature suggests that receptors are asymmetrically expressed in the renal epithelial cells: A1-adenosine
receptors and
2-ARs are thought to mediate the effects
of agonist exposure at the apical membrane (17,
64, 96), whereas the
2B-AR is
known to be expressed at the basolateral membrane of the proximal tubule cells (68). In this context, it has been proposed
that apical
1-AR requires endocytosis to activate a
basolateral AC in proximal tubule epithelial cells of rat kidney
(64), which essentially express the AC6 isoform. On the
other hand, Okusa et al. (123) have concluded that, in
LLC-PK1 cells stably transfected with two G protein-coupled
receptors known to be targeted to the opposite domains in the renal
epithelial cells, the apical A1-adenosine receptor and the
basolateral
2B-AR, the AC activity is present at, or
near, the apical and the basolateral domains of the cells and that the
local AC activity can be regulated by Gi-coupled receptors.
It therefore appears very important to determine the targeting of the
various AC isoforms by using modern tools, such as flag labeling and
confocal microscopy.
Depending on the cell type, the cytosolic free Ca2+ concentration ([Ca2+]i) can be increased by various mechanisms. Activation of PLC-coupled receptors, by substance K or bradykinin, causes an inhibition of the agonist-stimulated cAMP production: in C6-2B cells, which express mainly AC6, the inhibition of cAMP accumulation is temporally correlated with, and dependent on, initial [Ca2+]i rise evoked by Ca2+-mobilizing agents (34). In parathyroid cells, where extracellular free Ca2+ concentration ([Ca2+]e) plays a crucial role, eliciting a negative feedback on parathyroid hormone secretion, increasing [Ca2+]e stimulates PLC activity and inhibits hormone-dependent cAMP accumulation (21, 82). In kidney, the cortical thick ascending limb ensures the cAMP-stimulated paracellular Ca2+ reabsorption from the lumen to the extracellular fluid compartment of the renal tubule; an increase in [Ca2+]e decreases the hormone-dependent cAMP accumulation by a mechanism that is independent of direct inhibition of AC activity, most probably AC6 (18, 155). In both bovine parathyroid cells and in rat kidney, a Ca2+-sensing receptor has been described that is activated by [Ca2+]e and stimulates PLC activity. In the cortical thick ascending limb cells of rat kidney, this receptor is coexpressed with the Ca2+-inhibitable AC, AC6 (37). An increase in extracellular Ca2+, coupled to PLC activation, induces a dose-dependent inhibition of the vasopressin-dependent cAMP increase (155). Experiments on microperfused rat cortical thick ascending limb have demonstrated that [Ca2+]e inhibits the transtubular electrolyte reabsorption (37), which supports a direct physiological role for an inhibition of AC6. The best hypothesis to explain the inhibitory effect of extracellular Ca2+ on AC activity in the thick ascending limb (37) is an inhibition elicited by an increase in intracellular Ca2+ (due to capacitative Ca2+ entry and/or Ca2+ release).
Invalidation of the Gs
-subunit in mice has shed
additional light on those mechanisms. In the thick ascending limb,
acute exposure to vasopressin increases NaCl transport probably through the apical Na-K-2Cl cotransporter. In the heterozygous
Gs
-knockout mice, the Na-K-2Cl cotransporter protein is
markedly reduced (48). In parallel, cAMP production, on
glucagon stimulation, and the abundance of AC6 are diminished in thick
ascending limb. In this system the abundance of AC6 is probably
regulated by a feed-forward regulatory mechanism (48), the
amount of AC6 being positively correlated with that of
Gs
and not subject to compensatory overexpression. Along
the same line, it is interesting to note that all the AC isoforms
expressed in the kidney were found to be depressed in the homozygous
Brattleboro rats, animals with an hereditary diabetes insipidus (DI)
lacking antidiuretic hormone (143), when one would have
expected some compensatory increase.
AC5 and AC6 are inhibitable by both Gi-coupled receptors and Ca2+. The characteristics of inhibitory regulation of AC activity by Ca2+ and G proteins were examined in dispersed gastric smooth muscle cells. These inhibitions can be mediated independently by Gi proteins and Ca2+ influx. When both mechanisms are triggered concurrently, inhibition is exclusively mediated by Gi proteins (116).
The Role of Ca2+/Calmodulin-Activated ACs in Brain Function
The central nervous system possesses all the forms of ACs characterized so far. The presence of Ca2+-stimulated cyclase activity has been known for many years and is now ascribed to the two specific isoforms, AC1 and AC8.AC1 has been the first isoform to be cloned (86). It can be activated by Gs-coupled receptors as well as by the Ca2+-calmodulin complex and, therefore, can function as a coincidence detector for the two signaling pathways. AC8 is also stimulated by Ca2+/calmodulin, albeit at a 5-10 times higher Ca2+ concentration. Although there is not definite evidence for it, AC8 is supposed to rather act as a pure Ca2+ detector (190).
AC1 is present in various areas of the brain, mainly the cortex, the hippocampus, the cerebellum, and the pineal gland. Interestingly, research in mammals has been driven by previous results obtained in Drosophila concerning mutations affecting memory. The flies can be trained to avoid a particular odor by coupling exposure to that odor with an electric shock. The rutabaga- mutant flies fail to avoid the "trained" odor and appear to be deficient in Ca2+-activated AC (43, 44, 94). This form of AC has been characterized and cloned by Levin et al. (89) and appears most similar to the mammalian AC1, with the exception of a very long COOH terminal, the function of one-half of which is unknown. A single point mutation at position 1026 is sufficient to cause the complete loss of cyclase activity in vitro and to result in the biochemical and phenotypical defects seen in vivo. All this points to a very important role of AC1 in learning and memory.
Disruption of the AC1 gene in mice results in a loss of Ca2+-sensitive AC activity in cerebellum, cortex, and hippocampus by 62, 38, and 46%, respectively (151, 172, 186), with no obvious anatomic differences. The mutant mice exhibit a dampening of the long-term potentiation in the hippocampus and a near-blockade in the cerebellum (171). A spontaneous loss-of-function mutation in the AC1 gene has also been reported in mice (barrelless) (2, 182). This mutation is associated with a partial failure of patterning of the whisker-to-barrel pathway, resulting in an incomplete formation of barreloids and an aberrant segregation of thalamocortical afferent arborization. It is therefore very likely that the AC1 signaling pathway plays an important role in pattern formation of the brain and in some forms of synaptic plasticity, including learning and memory storage. Whether this might be related to the pattern of appearance of AC1 during development as we reported (104) merits further investigation.
At the same time, AC1 does function as a good coincidence detector, and
this is well demonstrated in the pineal gland (170), where
AC1 is activated by norepinephrine via both the
-AR (through Gs
) and the
1-AR (through
Ca2+ release), to increase cAMP formation and ultimately
N-acetyl transferase and melatonin synthesis. AC1 synthesis
undergoes a striking circadian variation that makes it a key regulating
step in melatonin production and release.
AC8 is also a major isoform in the brain although it has also been
found in testis (36, 63) and lung
(115). In the brain, it is mainly present throughout
(16, 102, 115), especially in
the cortex, cerebellum, brain stem, hypothalamus, hippocampus, and
olfactory bulb. The specific localization in hypothalamic nuclei
suggests a role in neuroendocrine function whereas its specific
increase in some regions of the brain, and especially in the locus
c
ruleus during morphine administration and withdrawal, points to a
role in drug dependence (87, 103).
It is interesting to note that another type of cyclase, AC9, is
expressed to a high level in the brain (5). This isoform is weakly sensitive to forskolin and is not directly regulated by
Ca2+ or 
. It has been proposed to be inhibited by the
Ca2+/calmodulin-activated protein phosphatase 2B
(calcineurin), at least in mice (4, 6) but
maybe not in humans (61). The kinase that potentially
phosphorylates AC9 has not been identified. Interestingly, invalidation
of this isoform in Caenorhabditis elegans prevents
Gs
-induced neuronal cell death (13,
84). AC9 might therefore be an important regulator,
especially related to signaling in motoneurons. It is tempting to
speculate that AC9 may also play such a role in mammals although there
is no evidence for it at present.
Is a Specific Isoform Associated With Cell Differentiation?
In many cell types, the intracellular concentration of cAMP affects the progression within the cell cycle. In some of them, growth-stimulatory effects have been observed, whereas in others inhibitory effects have been reported (46, 97). In most of the cases, it appears that elevation of intracellular cAMP, through Gs
or forskolin activation
of AC, blocks the transfer of signal from the growth factor receptors
to MAP kinases, through PKA-dependent phosphorylation (23,
62, 184). As with many other undifferentiated or dedifferentiated cell types in culture, NIH3T3 cells express AC6 at
a high level, whose activity is inhibited by a variety of signals,
including Ca2+, PKA, and PKC (75,
146). To investigate the potential role of a specific AC
isoform in regulating proliferative responses, Smit et al.
(147) have transfected NIH3T3 cells with different AC
isoforms. They observed that overexpression of AC6 has no effect on the
rate of cell proliferation; by contrast, overexpression of AC2, an
isoform that is stimulated by PKC, resulted in inhibition of cell cycle
progression and increased doubling time, resulting from an inhibition
of signal flow from Ras to mitogen-activated protein kinase. Moreover,
the suppressive effect of the platelet-derived growth factor-induced
DNA synthesis was completely reversed by coexpression of a dominant
negative mutant of PKA. Thus expression of specific isoforms of AC
might function as an homeostatic element of proliferation.
The importance of cAMP in cell differentiation has been reported in various organisms and cell types. However, the molecular mechanism involved is still poorly known. To investigate the role of specific isoforms of AC during cell differentiation, we have used the P19 embryonic carcinoma cells, which are pluripotent stem cells that can mimic in vitro the first stages of cellular differentiation occurring during mouse embryogenesis (106). Retinoic acid treatment of P19 cells leads to neuronal differentiation, whereas DMSO induces differentiation into mesodermal derivatives including cardiomyocytes. We have shown that neuronal differentiation of P19 cells, which is mediated by the cAMP/PKA cascade in vivo as well as in vitro (126, 176), exhibits a stage-specific upregulation of specific mRNA isoforms of AC, AC2, AC5, and AC8 (92). On the other hand, mesodermal differentiation of P19 cells is accompanied by an increase in mRNAs for AC2, AC5, and AC6 (93). In both cases, cell contacts and inhibition of cell proliferation are required before differentiation. In both cases, the total AC activity was increased at least by 10-fold. This increase is mainly related to an increase in AC2 level, because the specific activity of AC2 is much higher than that of the other ACs (129). Together with results obtained in transfected cells, these results favor the hypothesis that AC2 expression at a high level is a prerequisite for arrest of cell proliferation, then allowing cell differentiation. It is noteworthy that AC2 and AC7, both of which are stimulated by PKC, are expressed largely in postmitotic neural cells and platelets, whereas cells that retained proliferative capability do not express significant levels of isoforms that can be activated by growth factors.
Isoform-Specific Regulations During Development
The two best-studied systems to date are the heart and the brain. We (52) and others (169) have demonstrated that, although the two major isoforms in rat heart, AC5 and AC6 mRNAs, are equivalent at birth, AC5 mRNA becomes predominant in the adult rat heart. Because the two forms are clearly related and are similarly regulated by Ca2+, there is no obvious physiological correlation for this genetic switch. One could hypothesize that the shift from AC6 to AC5 could be related to the state of cellular differentiation. Interestingly, AC5 is absent in skeletal muscle, where the major isoform is AC9 (Table 1).After denervation, the levels of AC9 and AC2 mRNAs decrease in skeletal muscle whereas those of AC6 and AC7 are increased, the latter pattern being identical to that observed in the fetus and the neonate. These results indicate that changes in AC activities as well as AC mRNAs play an important role in muscle development as well as during muscle atrophy (154).
In rat brain, we have studied the developmental pattern of AC1, AC2, and AC5 during the postnatal period by in situ hybridization (104). One of the very interesting features found is that during the early postnatal stage, AC1 transcripts are very high in the central cortex, the striatum, and several regions involved in the sensory relay nuclei (such as the superior and inferior colliculus). These AC transcripts subsequently decrease rapidly in these regions, to be replaced, for example, by the AC5 transcript in the striatum, whereas they dramatically increase in the cerebellum and the hippocampus. These results demonstrate that the various ACs are expressed in the developing rat brain in a region- and age-specific manner and that they may thus be important not only for synaptic transmission (e.g.. for long-term potentiation and memory) but also in the differentiation and maturation of synapses between neuronal cells, especially in sensory pathways.
Is a Specific Isoform Associated With the Development and Function of Mature Spermatozoa?
The cAMP-dependent pathway is known to play a critical role in the expression of genes involved in haploid germ cell differentiation, and several reports have indicated the existence of a unique soluble form of AC in mammalian germ cells with properties that differ from those of somatic cells: this AC activity is insensitive to G proteins, fluoride, and forskolin and is associated with a low-molecular-weight fraction, ranging from 42 to 69 kDa (3, 83, 121, 148, 149). The low-molecular-weight isoform has been described in the cytosol of the early stages of spermatide cells, whereas the AC activity is membrane-bound in mature spermatozoa (3). That specialized isoforms are required for germ cell differentiation is suggested by observations in lower organisms, where an AC with unique structure and properties is expressed during the germinative stage (130).A soluble AC isoform with a molecular mass of 48 kDa has recently been isolated from rat testis, and its cDNA has been sequenced (14). In transfected cells, this isoform seems to possess the catalytic properties of the soluble AC described in spermatid cells: it is Mn2+-dependent and insensitive to G protein or forskolin regulation. This isoform, preferentially expressed in testis, is unique because its presumptive catalytic domains are closely related to cyano- and myxobacteria ACs. However, it originates from a larger protein of 187 kDa, most probably by a proteolytic cleavage. Nevertheless, the distribution within the different types of cells present in testis, somatic, and germinal cells has not been reported, and it is difficult to attribute a definite function to this small form.
More interestingly, AC3, which has been identified as being specific to
the olfactory apparatus, was found specifically expressed in rat male
germ cells, from pachytene spermatocytes to spermatids, in the same
subpopulation as other elements of the olfactory transduction pathway,
putative odorant receptors, G
olf, and the transcription factor Olf-1 (35, 57). A more detailed study
has indicated that AC3 is localized in the acrosome membrane of
spermatids (57), suggesting a role of this AC in the
biogenesis of acrosome and possibly in gamete production and
fertilization. In olfactory epithelium, both AC3 and the olfactory
G
- subunit G
olf have been localized to the same
receptor cell compartment, the distal segments of the olfactory cilia
(78, 107). Moreover, a selective localization
of G
olf, putative odorant receptors, and associated desensitizing proteins have been shown in elongated spermatids and the
midpiece of the sperm tail (142, and N. Defer, unpublished observations). Taken together, these observations are consistent with
the hypothesis that the signal transduction system used in olfaction
may also be used in the function of the mature spermatozoa and may be
implicated in sperm chemotaxis during fertilization.
Is a Specific Isoform Associated with a Specific Hormone Action?
Studies from the laboratory of Patel and colleages (118) have shown that epidermal growth factor (EGF) produces inotropic and chronotropic action in rat heart by increasing cAMP accumulation. This EGF-elicitated stimulation of cellular cAMP accumulation in the heart is the result of stimulation of AC activity by a mechanism involving the participation of a Gs protein (119) and the tyrosine kinase activity of the EGF receptor (117). The EGF-receptor tyrosine kinase can phosphorylate Gs
on tyrosine residues, and this phosphorylation increases its
ability to stimulate AC activity. HEK-293 cells have been transfected
with different isoforms of ACs, AC1, AC2, AC5, and AC6
(25). EGF increased AC activity and cAMP accumulation only
in cells expressing AC5. Because all isoforms are potentially
stimulated by Gs
, these results suggest AC5 that
activation reflects either the specific interaction between AC5 and the
tyrosine-phosphorylated form of Gs or the presence of an
additional regulatory element, potentially PKC-
, which could modify
the sensitivity of the enzyme. In heart, growth factor-stimulated production of PIP3 through PI3K is able to
stimulate PKC-
and activate AC5 by a mechanism independent of
Ca2+ (91, 120).
Along the same line, another model is provided by the ATP stimulation of AC through purinergic receptors. For long time, it has been reported that extracellular purines act as intercellular messengers and exert a widespread influence on cellular function by acting through different types of cell surface receptors. Activation of P2Y purinoceptors has been linked to changes in the cAMP level. According to the cell type, purinoceptor activation may result in an increase in basal and stimulated cAMP production as observed in microvascular endothelial cells from adrenal medulla and in heart. ATP, which is released from the terminal sympathetic nerve together with norepinephrine under physiological conditions, increases the contractility of isolated cardiac preparations (88) and induces chronotropic and dromotropic effect on mammalian sinoatrial node, by binding to P2 purinoceptors. In ischemic hearts, ATP could also be a source of arrhythmia. In an attempt to demonstrate the mechanism by which purinergic stimulation of cardiomyocytes increases intracellular cAMP, Pucéat et al. (135) demonstrated that purinergic stimulation of cardiomyocytes increased intracellular cAMP content through a Gs-mediated activation of an AC (135). Using HEK-293-transfected cells, they demonstrated that AC5, but not AC4 or AC6, is responsive to the purinergic stimulation. Moreover, purinergic activation of AC is additive to that of isoproterenol in cardiomyocytes. It was thus suggested that purines might act as modulators of cell functions already regulated by other neuromediators released from the same nerve terminals.
During the course of pregnancy and at the onset of parturition, the
contractile activity of the uterus is under the control of steroid
hormones. Progesterone, which culminates at midpregnancy, enhances
myometrium relaxation by increasing the Gs-coupled
2-AR cAMP cascade (29, 50,
99, 174). The regulation of myometrium contractility implicates the AC-stimulatory pathways as a key component
modulating the intracellular cAMP concentration and thus the
contractile state of the uterus. Northern blot analysis revealed the
presence of numerous isoforms in both humans and rats, AC6 being the
major ones (109, 153). The level of
expression of the AC mRNAs increases 1.7- to 3.4-fold during the course
of pregnancy and diminishes near term and after delivery. In agreement with these findings, both basal and forskolin-stimulated AC activities exhibited a two- to threefold increase during the course of pregnancy, followed by a slight decrease near term (153). These data
indicate that changes in the level of AC mRNA (and presumably proteins) that occur during pregnancy and after delivery may contribute to the
essential role of cAMP in maintaining uterus quiescence. In this
respect, the papers by Mhaouty et al. (108,
109) are particularly relevant. They have identified two
types of Gi-coupled
2-AR in rat myometrium:
2A-AR transcript is present at midpregnancy, whereas
2B-AR mRNA is detected at term (108). At
midpregnancy, the activation of the
2A-AR/Gi
signaling cascade by micromolar concentration of clonidine, results in
a potentiation of the
2-AR stimulation of the AC
activity in myometrial membranes (108); addition of
-transducin, a G
scavenger, blocks this potentiation in a
dose-dependent manner (109). At the time of delivery,
[Ca2+]i dramatically increases in response to
external stimuli and may inhibit AC6 activity, which is also expressed
at a high level. Thus, during the early stages of pregnancy, when it is
important to maintain a relaxed state of myometrium, the
2A-AR activation augments the effect of isoproterenol on
the cellular cAMP concentration, promoting smooth muscle relaxation.
This effect is probably mediated through G
activation of AC2. At
the later stage of pregnancy, when contraction is important,
2-AR inhibits the stimulation of AC by the
-AR
agonists. Marjamaki et al. (101) have proposed that such a
switch in the consequences of
2-AR stimulation could be
explained by a change in the phosphorylation status of AC2.
cAMP and Drug Dependence
Acute administration of morphine or opioids causes a decrease of AC activity via the Gi pathway, and chronic administration leads to the classic states of tolerance and dependence (122). Dependence includes behavioral and physical signs, behind which is a complex array of biochemical phenomena. Among the various mechanisms underlying these phenomena, one of the most studied since the early work of Sharma et al. (141) on NG 108-15 cells is an upregulation of the cAMP system, including AC, PKA, and the transcriptional factor CREB. Thus, after a long-term in vivo morphine treatment followed by administration of the antagonist naloxone, an increase in the AC activity in the cerebral cortex (45, 98) and in striatum (105, 164) but not in the cerebellum devoid of receptor can be observed. For example, after morphine withdrawal, there is a 30% increase in basal and forskolin-stimulated AC activity in the striatum, an increase that is no longer seen in µ receptor-deficient animals (105). It is also noteworthy that, in an extensive study of the critical role of cAMP in morphine dependence in the rat, Lane-Ladd et al. (87) found an increase in AC1, AC8, PKA, and CREB in the locus coeruleus, a major site responsible for the physical signs of dependence. These data confirm our earlier results on the involvement of AC8 in the locus coeruleus (103).These changes have been reproduced in various cell culture systems, and
one can more or less readily observe an upregulation of AC activity
that has the following characteristics: 1) it can be
observed after treatment with a variety of inhibitory ligands, including muscarinic agents and somatostatin (167);
2) it is long lived; 3) depending on the system
studied, it may or may not involve a transcriptional step
(7); 4) the 
-subunits seem to play a
specific, although not direct, role (8, 19, 168); and 5) the effect may be specific for
certain isoforms of AC (9, 196). Along the
same line, it is worth noting that opiates can have bimodal acute
effects on cAMP production in the myenteric plexus, depending on the
concentration used (177).
Most of the recent results originate from studies involving artificial, transient, or permanent transfections of various AC isoforms. The nature and stoichiometry of the components involved may provide spurious results, and therefore these data should be considered with caution until they can be directly confirmed in better models. However, the upregulation of the AC system is at present the best explanation available for the dependent state after opiate administration.
Interestingly, the recently described model of cannabis withdrawal
confirms this model. The recent availability of a specific CB1
antagonist, SR-141716A, has allowed one to set up an in vivo model of
cannabis abstinence. After 6 days of treatment with
-9 tetrahydrocannabinol, followed by the administration of the antagonist, mice exhibit several somatic signs (wet-dog shakes, facial rubbing, ataxia, hunched posture, mastication) that could be interpreted as
being part of a withdrawal syndrome. Interestingly, the same animals
exhibit a 100% increase in the basal, forskolin-, and Ca2+/calmodulin-stimulated AC activity in the cerebellum
(rich in CB1 receptors) but not in the cortex or the striatum
(70).
Alcohol is one of the most widely abused drugs in the world. Although ethanol does not act through a specific receptor, there is increasing evidence that the observed effects result from specific alterations. Among the various biological markers associated with certain subtypes of chronic alcoholism, a low-platelet AC activity has been proposed to reflect a genetic predisposition to alcohol dependence. In most cell culture systems, acute exposure to ethanol treatment has been found to potentiate the receptor-mediated cAMP synthesis. In contrast, chronic exposure often causes a decrease in cAMP production. Parsian et al. (127) have observed that basal and fluoride-stimulated platelet AC activity of alcoholic patients have lower value than in control subjects (127). Moreover, Ikeda et al. (71) have reported that 5'-guanylyl imidodiphosphate- and forskolin-stimulated platelet AC activity may help to distinguish between subtypes of alcoholic patients (those who develop a negative mood in response to drinking, those who continue drinking despite health effects, those who become violent while drinking) (71). Recently, Ratsma et al. (137) have described that the forskolin-stimulated AC activity is considerably lower in platelets of children of alcoholic patients (children who are at high risk for alcoholism but not yet consuming alcohol). Furthermore, the reduced AC activity was only observed in platelets of children from multigenerational family of alcoholism. The platelet AC may therefore represent a trait marker for genetic predisposition to alcoholism.
In human platelets, the major AC isoform expressed is AC7 (67). A selective effect of ethanol on cAMP synthesis through a specific AC isoform has been demonstrated by using HEK-293 cells transfected with different types of ACs: the stimulation of cAMP generation by ethanol was found two- to threefold greater in AC7-transfected cells than in cells transfected with other ACs (197). Recently it has been proposed that ethanol may act by promoting phosphorylation of AC7 (136).
To better understand the mechanism of action of ethanol, animal models have been used. On exposure to ethanol, Drosophila displays behavior quite similar to that observed on ethanol intoxication in rodents and humans. More readily accessible to genetic analysis, Drosophila represents a very attractive model to investigate the molecular mechanisms underlying ethanol dependence. Moore et al. (114) have demonstrated that ethanol intoxication in Drosophila is modulated through the cAMP pathway and probably through AC1 activity (114). Indeed, loss-of-function mutations in rutabaga AC (the Drosophila AC1) increases the sensitivity to ethanol, whereas flies lacking both the cAMP phosphodiesterase (dunce) and the isoform AC1 (rutabaga) are not different from wild-type control flies.
| |
GENERAL CONCLUSIONS |
|---|
|
|
|---|
The existence of large families of proteins at each level of the cAMP signaling pathways (receptors, G proteins, cyclases, phosphodiesterases) has opened the Pandora's box of combinatorial regulations. No longer can we safely assume that a given hormone will always increase, or decrease, the cAMP content of a cell. We are overwhelmed by the variety of potential regulations of AC activity. Yet, most recent progress in the field of AC has focused on the structural components of the enzymes involved in potential regulations more than on their physiological relevance. For some time, we will probably have to face the usual problem of sorting out important regulatory loops from spurious ones.
In particular, we are still lacking data from knockout experiments with the all various isoforms of AC (only the knockout of AC1 has been reported to date). As cAMP plays a key role during development, conditional knockouts in various organs will be probably necessary. This is all the more needed as a compensatory increase of an isoform to supplement the loss of another one cannot be excluded. From this point of view, it is striking that no pathology linked to the alteration of a cyclase isoform has been reported to far, with the exception of the altered sensory patterning of somatosensory cortex of barrelless mice, whereas the pathology linked to the other components of the cAMP signaling pathway (receptors, G protein) is well known.
Therefore, some of the questions that are likely to be crucial in the
years to come might be the following. 1) To what extent are
the various isoforms redundant? 2) To what extent are the various cross-talks, potentially regulating cAMP formation, really physiological? For example, if the pineal gland is a good model for AC1
being a potential coincidence detector (for Gs
and
calmodulin/Ca2+), we have to admit that we have no direct
experimental evidence for it. Similarly, the potential inhibition of
AC5 and AC6 by Ca2+ is still in need of a convincing
demonstration. 3) In the cascade "receptor-G
protein-effector," AC is probably limiting, as demonstrated by Post
et al. (131) in various systems. However, is the likely cellular compartmentalization of AC interferring with the stoichiometry of the enzyme with respect to the other components? 4) Are
the overexpressed, extraneous isoforms localized in the correct
compartments? 5) To what extent is the demonstration that
the cAMP signaling cascade occurring within a restricted,
caveolin-enriched, microdomain of the plasma membrane
(140), a constant phenomenon? 6) Are there endogenous analogs of forskolin or adenine nucleoside polyphosphate (39, 77) that could further regulate the
activities of the different isoforms?
| |
ACKNOWLEDGEMENTS |
|---|
This work has been supported by Institut National de la Santé et de la Recherche Médicale, the University Paris-Val de Marne, the Fondation de France, the Caisse Nationale d'Assurance Maladie, the Fondation Retina France, and the Mission Interministérielle de Lutte contre la Drogue et la Toxicomanie.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: J. Hanoune, Institut National de la Santé et de la Recherche Médicale U-99 Hôpital Henri Mondor, F-94010 Créteil, France (E-mail: hanoune{at}im3.inserm.fr).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
| |
REFERENCES |
|---|
|
|
|---|
1.
Abdel-Halim, SM,
Guenifi A,
He B,
Yang B,
Mustafa M,
Hojeberg B,
Hillert J,
Bakhiet M,
and
Efendic S.
Mutations in the promoter of adenylyl cyclase (AC)-III gene, overexpression of AC-III mRNA, and enhanced cAMP generation in islets from the spontaneously diabetic GK rat model of type 2 diabetes.
Diabetes
47:
498-504,
1998[Abstract].
2.
Abdel-Majid, RM,
Leong WL,
Schalkwyk LC,
Smallman DS,
Wong ST,
Storm DR,
Fine A,
Dobson MJ,
Guernsey DL,
and
Neumann PE.
Loss of adenylyl cyclase I activity disrupts patterning of mouse somatosensory cortex.
Nature Genet
19:
289-291,
1998[Web of Science][Medline].
3.
Adamo, S,
Conti M,
Geremia R,
and
Monesi V.
Particulate and soluble adenylate cyclase activities of mouse male germ cells.
Biochem Biophys Res Commun
97:
607-613,
1980[Web of Science][Medline].
4.
Antoni, FA,
Barnard RJ,
Shipston MJ,
Smith SM,
Simpson J,
and
Paterson JM.
Calcineurin feedback inhibition of agonist-evoked cAMP formation.
J Biol Chem
270:
28055-28061,
1995
5.
Antoni, FA,
Palkovits M,
Simpson J,
Smith SM,
Leitch AL,
Rosie R,
Fink G,
and
Paterson JM.
Ca2+/calcineurin-inhibited adenylyl cyclase, highly abundant in forebrain regions, is important for learning and memory.
J Neurosci
18:
9650-9661,
1998
6.
Antoni, FA,
Smith SM,
Simpson J,
Rosie R,
Fink G,
and
Paterson JM.
Calcium control of adenylyl cyclase: the calcineurin connection.
Adv Second Messenger Phosphoprotein Res
32:
153-172,
1998[Medline].
7.
Avidor-Reiss, T,
Bayewitch M,
Levy R,
Matus-Leibovitch N,
Nevo I,
and
Vogel Z.
Adenylyl cyclase supersensitization in µ-opiod receptor-transfected chinese hamster ovary cells following chronic opioid treatment.
J Biol Chem
270:
29732-29738,
1995
8.
Avidor-Reiss, T,
Nevo I,
Levy R,
Pfeuffer T,
and
Vogel Z.
Chronic opioid treatment induces adenylyl cyclase V superactivation-involvement of G
.
J Biol Chem
271:
21309-21315,
1996
9.
Avidor-Reiss, T,
Nevo I,
Saya D,
Bayewitch M,
and
Vogel Z.
Opiate-induced adenylyl cyclase superactivation is isozyme-specific.
J Biol Chem
272:
5040-5047,
1997
10.
Bakalyar, HA,
and
Reed RR.
Identification of a specialized adenylyl cyclase that may mediate odorant detection.
Science
250:
1403-1406,
1990
11.
Bayewitch, ML,
Avidor-Reiss T,
Levy R,
Pfeuffer T,
Nevo I,
Simonds WF,
and
Vogel Z.
Differential modulation of adenylyl cyclases I and II by various G
subunits.
J Biol Chem
273:
2273-2276,
1998
12.
Bayewitch, ML,
Avidor-Reiss T,
Levy R,
Pfeuffer T,
Nevo I,
Simonds WF,
and
Vogel Z.
Inhibition of adenylyl cyclase isoforms V and VI by various G
subunits.
Faseb J
12:
1019-1025,
1998
13.
Berger, AJ,
Hart AC,
and
Kaplan JM.
G
s-induced neurodegeneration in Caenorhabditis elegans.
J Neurosci
18:
2871-2880,
1998
14.
Buck, J,
Sinclair ML,
Schapal L,
Cann MJ,
and
Levin LR.
Cytosolic adenylyl cyclase defines a unique signaling molecule in mammals.
Proc Natl Acad Sci USA
96:
79-84,
1999
15.
Bygrave, FL,
and
Roberts HR.
Regulation of cellular calcium through signaling cross-talk involves an intricate interplay between the actions of receptors, G-proteins, and second messengers.
FASEB J
9:
1297-1303,
1995[Abstract].
16.
Cali, JJ,
Zwaagstra JC,
Mons N,
Cooper DM,
and
Krupinski J.
Type VIII adenylyl cyclase. A Ca2+/calmodulin-stimulated enzyme expressed in discrete regions of rat brain.
J Biol Chem
269:
12190-12195,
1994
17.
Casavola, V,
Guerra L,
Reshkin SJ,
Jacobson KA,
Verrey F,
and
Murer H.
Effect of adenosine on Na+ and Cl
currents in A6 monolayers. Receptor localization and messenger involvement.
J Membr Biol
151:
237-245,
1996[Web of Science][Medline].
18.
Chabardes, D,
Firsov D,
Aarab L,
Clabecq A,
Bellanger AC,
Siaume-Perez S,
and
Elalouf JM.
Localization of mRNAs encoding Ca2+-inhibitable adenylyl cyclases along the renal tubule. Functional consequences for regulation of the cAMP content.
J Biol Chem
271:
19264-19271,
1996
19.
Chakrabarti, S,
Rivera M,
Yan SZ,
Tang WJ,
and
Gintzler AR.
Chronic morphine augments G
/Gs
stimulation of adenylyl cyclase: relevance to opioid tolerance.
Mol Pharmacol
54:
655-662,
1998
20.
Chaudhry, A,
Muffler LA,
Yao R,
and
Granneman JG.
Perinatal expression of adenylyl cyclase subtypes in rat brown adipose tissue.
Am J Physiol Regulatory Integrative Comp Physiol
270:
R755-R760,
1996
21.
Chen, CJ,
Barnett JV,
Congo DA,
and
Brown EM.
Divalent cations suppress 3',5'-adenosine monophosphate accumulation by stimulating a pertussis toxin-sensitive guanine nucleotide-binding protein in cultured bovine parathyroid cells.
Endocrinology
124:
233-239,
1989
22.
Chen, J,
and
Iyengar R.
Inhibition of cloned adenylyl cyclases by mutant-activated Gi-
and specific suppression of type 2 adenylyl cyclase inhibition by phorbol ester treatment.
J Biol Chem
268:
12253-12256,
1993
23.
Chen, J,
and
Iyengar R.
Suppression of Ras-induced transformation of NIH 3T3 cells by activated G
s.
Science
263:
1278-1281,
1994
24.
Chen, Y,
Harry A,
Li J,
Smit MJ,
Bai X,
Magnusson R,
Pieroni JP,
Weng G,
and
Iyengar R.
Adenylyl cyclase 6 is selectively regulated by protein kinase A phosphorylation in a region involved in G
s stimulation.
Proc Natl Acad Sci USA
94:
14100-14104,
1997
25.
Chen, Z,
Nield HS,
Sun H,
Barbier A,
and
Patel TB.
Expression of type V adenylyl cyclase is required for epidermal growth factor-mediated stimulation of cAMP accumulation.
J Biol Chem
270:
27525-27530,
1995
26.
Chiono, M,
Mahey R,
Tate G,
and
Cooper DM.
Capacitative Ca2+ entry exclusively inhibits cAMP synthesis in C6-2B glioma cells. Evidence that physiologically evoked Ca2+ entry regulates Ca(2+)-inhibitable adenylyl cyclase in non-excitable cells.
J Biol Chem
270:
1149-1155,
1995
27.
Choi, EJ,
Wong ST,
Dittman AH,
and
Storm DR.
Phorbol ester stimulation of the type I and type III adenylyl cyclases in the whole cells.
Biochemistry
32:
1891-1894,
1993[Medline].
28.
Choi, E-J,
Xia Z,
and
Storm DR.
Stimulation of the type 3 olfactory adenylyl cyclase by calcium and calmodulin.
Biochemistry
31:
6492-6498,
1992[Medline].
29.
Cohen-Tannoudji, J,
Vivat V,
Heilman J,
Legrand C,
and
Maltier JP.
Regulation by progesterone of the high-affinity state of myometrial
-adrenergic receptor and of adenylate cyclase activity in the pregnant rat.
J Mol Endocrinol
6:
137-145,
1991
30.
Cooper, DM,
Karpen JW,
Fagan KA,
and
Mons NE.
Ca(2+)-sensitive adenylyl cyclases.
Adv Second Messenger Phosphoprotein Res
32:
23-51,
1998[Medline].
31.
Cooper, DM,
Mons N,
and
Fagan K.
Ca2+-sensitive adenylyl cyclases.
Cell Signal
6:
823-840,
1994[Web of Science][Medline].
32.
Cooper, DM,
Mons N,
and
Karpen JW.
Adenylyl cyclases and the interaction between calcium and cAMP signalling.
Nature
374:
421-424,
1995[Medline].
33.
Cooper, DM,
Yoshimura M,
Zhang Y,
Chiono M,
and
Mahey R.
Capacitative Ca2+ entry regulates Ca(2+)-sensitive adenylyl cyclases.
Biochem J
297:
437-440,
1994.
34.
Debernardi, MA,
Munshi R,
Yoshimura M,
Cooper DM,
and
Brooker G.
Predominant expression of type-VI adenylate cyclase in C6-2B rat glioma cells may account for inhibition of cyclic AMP accumulation by calcium.
Biochem J
293:
325-328,
1993.
35.
Defer, N,
Marinx O,
Poyard M,
Lienard MO,
Jegou B,
and
Hanoune J.
The olfactory adenylyl cyclase type 3 is expressed in male germ cells.
FEBS Lett
424:
216-220,
1998[Web of Science][Medline].
36.
Defer, N,
Marinx O,
Stengel D,
Danisova A,
Iourgenko V,
Matsuoka I,
Caput D,
and
Hanoune J.
Molecular cloning of the human type VIII adenylyl cyclase.
FEBS Lett
351:
109-113,
1994[Web of Science][Medline].
37.
De Jesus Ferreira, MC,
Helies-Toussaint C,
Imbert-Teboul M,
Bailly C,
Verbavatz JM,
Bellanger AC,
and
Chabardes D.
Co-expression of a Ca2+-inhibitable adenylyl cyclase and of a Ca2+-sensing receptor in the cortical thick ascending limb cell of the rat kidney. Inhibition of hormone-dependent cAMP accumulation by extracellular Ca2+.
J Biol Chem
273:
15192-15202,
1998
38.
De Rooij, J,
Zwartkruis FJ,
Verheijen MH,
Cool RH,
Nijman SM,
Wittinghofer A,
and
Bos JL.
Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP.
Nature
396:
474-477,
1998[Medline].
39.
Desaubry, L,
and
Johnson RA.
Adenine nucleoside 3'-tetraphosphates are novel and potent inhibitors of adenylyl cyclases.
J Biol Chem
273:
24972-24977,
1998
40.
Dessauer, CM,
and
Gilman AG.
Purification and characterization of a soluble form of mammalian adenylyl cyclase.
J Biol Chem
271:
16967-16974,
1996
41.
Dessauer, CW,
Scully TT,
and
Gilman AG.
Interactions of forskolin and ATP with the cytosolic domains of mammalian adenylyl cyclase.
J Biol Chem
272:
22272-22277,
1997
42.
Dessauer, CW,
Tesmer JJ,
Sprang SR,
and
Gilman AG.
Identification of a Gi
binding site on type V adenylyl cyclase.
J Biol Chem
273:
25831-25839,
1998
43.
Dudai, Y,
and
Zvi S.
Adenylate cyclase in the Drosophila memory mutant rutabaga displays an altered Ca2+ sensitivity.
Neurosci Lett
47:
119-124,
1984[Web of Science][Medline].
44.
Dudai, Y,
and
Zvi S.
Multiple effect of the activity of adenylyl cyclase from the Drosophila memory mutant rutabaga.
J Neurochem
45:
355-364,
1985[Web of Science][Medline].
45.
Duman, RS,
Tallman JF,
and
Nestler EJ.
Acute and chronic opiate-regulation of adenylate cyclase in brain: specific effects in locus coeruleus.
J Pharmacol Exp Ther
246:
1033-1039,
1988
46.
Dumont, JE,
Jauniaux JC,
and
Roger PP.
The cyclic AMP-mediated stimulation of cell proliferation.
Trends Biochem Sci
14:
67-71,
1989[Web of Science][Medline].
47.
Ebina, T,
Kawabe J,
Katada T,
Ohno S,
Homcy CJ,
and
Ishikawa Y.
Conformation-dependent activation of type II adenylyl cyclase by protein kinase C.
J Cell Biochem
64:
492-498,
1997[Web of Science][Medline].
48.
Ecelbarger, CA,
Yu S,
Lee AJ,
Weinstein LS,
and
Knepper MA.
Decreased renal Na-K-2Cl cotransporter abundance in mice with heterozygous disruption of the G(s)
gene.
Am J Physiol Renal Physiol
277:
F235-F244,
1999
49.
Edelhoff, S,
Villacres EC,
Storm DR,
and
Disteche CM.
Mapping of the adenylyl cyclase genes type I, II, III, IV, V, and VI in mouse.
Mamm Genome
6:
111-113,
1995[Web of Science][Medline].
50.
Elwardy-Merezak, J,
Maltier JP,
Cohen-Tannoudji J,
Lecrivain JL,
Vivat V,
and
Legrand C.
Pregnancy-related modifications of rat myometrial Gs proteins: ADP ribosylation, immunoreactivity and gene expression studies.
J Mol Endocrinol
13:
23-27,
1994
51.
Emala, CW,
Kumasaka D,
Hirshman CA,
and
Lindeman KS.
Adenylyl cyclase messenger ribonucleic acid in myometrium: splice variant of type IV.
Biol Reprod
59:
169-175,
1998
52.
Espinasse, I,
Iourgenko V,
Defer N,
Samson F,
Hanoune J,
and
Mercadier JJ.
Type V, but not type VI adenylyl cyclase mRNA accumulates in the heart during ontogenic development. Correlation with adenylyl cyclase activity.
J Mol Cardiol
27:
1789-1795,
1995[Web of Science][Medline].
53.
Federman, AD,
Conklin BR,
Schrader KA,
Reed RR,
and
Bourne HR.
Hormonal stimulation of adenylate cyclase through Gi-protein 
subunits.
Nature
356:
159-161,
1992[Medline].
54.
Furuyama, T,
Inagaki S,
and
Takagi H.
Distribution of the type II adenylyl cyclase in the rat brain.
Brain Res Mol Brain Res
19:
165-170,
1993[Medline].
55.
Gao, BN,
and
Gilman AG.
Cloning and expression of a widely distributed (type IV) adenylyl cyclase.
Proc Natl Acad Sci USA
88:
10178-10182,
1991
56.
Gao, T,
Puri TS,
Gerhardstein BL,
Chien AJ,
Green RD,
and
Hosey MM.
Identification and subcellular localization of the subunits of L-type calcium channels and adenylyl cyclase in cardiac myocytes.
J Biol Chem
272:
19401-19407,
1997
57.
Gautier-Courteille, C,
Salanova M,
and
Conti M.
The olfactory adenylyl cyclase III is expressed in rat germ cells during spermiogenesis.
Endocrinology
139:
2588-2599,
1998
58.
Granneman, JG.
Expression of adenylyl cyclase subtypes in Brown adipose tissues: neural regulation of type III.
Endocrinology
136:
2007-2012,
1995[Abstract].
59.
Gu, C,
and
Cooper DM.
Calmodulin-binding sites on adenylyl cyclase type VIII.
J. Biol Chem
274:
8012-8021,
1999
60.
Haber, N,
Stengel D,
Defer N,
Roeckel N,
Mattei-G M,
and
Hanoune J.
Chromosomal mapping of human adenylyl cyclase genes type III, type V and type VI.
Hum Genet
94:
69-73,
1994[Web of Science][Medline].
61.
Hacker, BM,
Tomlinson JE,
Wayman GA,
Sultana R,
Chan G,
Villacres E,
Disteche C,
and
Storm DR.
Cloning, chromosomal mapping, and regulatory properties of the human type 9 adenylyl cyclase (ADCY9).
Genomics
50:
97-104,
1998[Web of Science][Medline].
62.
Hafner, S,
Adler HS,
Mischak H,
Janosch P,
Heidecker G,
Wolfman A,
Pippig S,
Lohse M,
Ueffing M,
and
Kolch W.
Mechanism of inhibition of Raf-1 by protein kinase A.
Mol Cell Biol
14:
6696-6703,
1994
63.
Hanoune, J,
Pouille Y,
Tzavara E,
Shen T,
Lipskaya L,
Miyamoto N,
Suzuki Y,
and
Defer N.
Adenylyl cyclases: structure, regulation and function in an enzyme superfamily.
Mol Cell Endocrinol
128:
179-194,
1997[Web of Science][Medline].
64.
Hanson, AS,
and
Linas SL.
-Adrenergic receptor function in rat proximal tubule epithelial cells in culture.
Am J Physiol Renal Fluid Electrolyte Physiol
268:
F553-F560,
1995
65.
Harry, A,
Chen Y,
Magnusson R,
Iyengar R,
and
Weng G.
Differential regulation of adenylyl cyclases by G
s.
J Biol Chem
272:
19017-19021,
1997
66.
Hellevuo, K,
Berry R,
Sikela JM,
and
Tabakoff B.
Localization of the gene for a novel human adenylyl cyclase (ADCY7) to chromosome 16.
Hum Genet
95:
197-200,
1995[Web of Science][Medline].
67.
Hellevuo, K,
Yoshimura M,
Mons N,
Hoffman PL,
Cooper DM,
and
Tabakoff B.
The characterization of a novel human adenylyl cyclase which is present in brain and other tissues.
J Biol Chem
270:
11581-11589,
1995
68.
Huang, L,
Wei YY,
Momose-Hotokezaka A,
Dickey J,
and
Okusa MD.
2B-Adrenergic receptors: immunolocalization and regulation by potassium depletion in rat kidney.
Am J Physiol Renal Fluid Electrolyte Physiol
270:
F1015-F1026,
1996
69.
Hurley, JH.
Structure, mechanism, and regulation of mammalian adenylyl cyclase.
J Biol Chem
274:
7599-7602,
1999
70.
Hutcheson, DM,
Tzavara ET,
Smadja C,
Valjent E,
Roques BP,
Hanoune J,
and
Maldonado R.
Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol.
Br J Pharmacol
125:
1567-1577,
1998[Web of Science][Medline].
71.
Ikeda, H,
Menninger JA,
and
Tabakoff B.
An initial study of the relationship between platelet adenylyl cyclase activity and alcohol use disorder criteria.
Alcohol Clin Exp Res
22:
1057-1064,
1998[Web of Science][Medline].
72.
Iourgenko, V,
Kliot B,
Cann MJ,
and
Levin LR.
Cloning and characterization of a Drosophila adenylyl cyclase homologous to mammalian type IX.
FEBS Lett
413:
104-108,
1997[Web of Science][Medline].
73.
Ishikawa, Y,
Katsushika S,
Chen L,
Halnon NJ,
Kawabe-I J,
and
Homcy CJ.
Isolation and characterization of a novel cardiac adenylylcyclase cDNA.
J Biol Chem
267:
13553-13557,
1992
74.
Iwami, G,
Kawabe J,
Ebina T,
Cannon PJ,
Homcy CJ,
and
Ishikawa Y.
Regulation of adenylyl cyclase by protein kinase A.
J Biol Chem
270:
12481-12484,
1995
75.
Iyengar, R.
Molecular and functional diversity of mammalian Gs-stimulated adenylyl cyclases.
FASEB J
7:
768-775,
1993[Abstract].
76.
Jacobowitz, O,
Chen J,
Premont RT,
and
Iyengar R.
Stimulation of specific types of Gs-stimulated adenylyl cyclases by phorbol ester treatment.
J Biol Chem
268:
3829-3832,
1993
77.
Johnson, RA,
Desaubry L,
Bianchi G,
Shoshani I,
Lyons E, Jr,
Taussig R,
Watson PA,
Cali JJ,
Krupinski J,
Pieroni JP,
and
Iyengar R.
Isozyme-dependent sensitivity of adenylyl cyclases to P-site-mediated inhibition by adenine nucleosides and nucleoside 3'-polyphosphates.
J Biol Chem
272:
8962-8966,
1997
78.
Jones, DT,
and
Reed RR.
Golf: an olfactory neuron specific-G protein involved in odorant signal transduction.
Science
244:
790-795,
1989
79.
Kawabe, J,
Ebina T,
Toya Y,
Oka N,
Schwencke C,
Duzic E,
and
Ishikawa Y.
Regulation of type V adenylyl cyclase by PMA-sensitive and -insensitive protein kinase C isoenzymes in intact cells.
FEBS Lett
384:
273-276,
1996[Web of Science][Medline].
80.
Kawabe, J,
Iwami G,
Ebina T,
Ohno S,
Katada T,
Ueda Y,
Homcy CJ,
and
Ishikawa Y.
Differential activation of adenylyl cyclase by protein kinase C isoenzymes.
J Biol Chem
269:
16554-16558,
1994
81.
Kawasaki, H,
Springett GM,
Mochizuki N,
Toki S,
Nakaya M,
Matsuda M,
Housman DE,
and
Graybiel AM.
A family of cAMP-binding proteins that directly activate Rap1.
Science
282:
2275-2279,
1998
82.
Kifor, O,
Diaz R,
Butters R,
and
Brown EM.
The Ca2+-sensing receptor (CaR) activates phospholipases C, A2, and D in bovine parathyroid and CaR-transfected, human embryonic kidney (HEK293) cells.
J Bone Miner Res
12:
715-725,
1997[Web of Science][Medline].
83.
Kornblihtt, AR,
Flawia MM,
and
Torres HN.
Manganese ion dependent adenylate cyclase activity in rat testes: purification and properties.
Biochemistry
20:
1262-1267,
1981[Medline].
84.
Korswagen, HC,
van der Linden AM,
and
Plasterk RH.
G protein hyperactivation of the Caenorhabditis elegans adenylyl cyclase SGS-1 induces neuronal degeneration.
EMBO J
17:
5059-5065,
1998[Web of Science][Medline].
85.
Kozasa, T,
and
Gilman AG.
Purification of recombinant G proteins from Sf9 cells by hexahistidine tagging of associated subunits. Characterization of
12 and inhibition of adenylyl cyclase by
z.
J Biol Chem
270:
1734-1741,
1995
86.
Krupinski, J,
Coussen F,
Balkayar HA,
Tang W-J,
Feinstein PG,
Orth K,
Slaughter C,
Reed RR,
and
Gilman AG.
Adenylyl cyclase amino acid sequence: possible channel- or transporter-like structure.
Science
244:
1558-1564,
1989
87.
Lane-Ladd, SB,
Pineda J,
Boundy VA,
Pfeuffer T,
Krupinski J,
Aghajanian GK,
and
Nestler EJ.
CREB (cAMP response element-binding protein) in the locus coeruleus: biochemical, physiological, and behavioral evidence for a role in opiate dependence.
J Neurosci
17:
7890-7901,
1997
88.
Legssyer, A,
Poggioli J,
Renard D,
and
Vassort G.
ATP and other adenine compounds increase mechanical activity and inositol trisphosphate production in rat heart.
J Physiol (Lond)
401:
185-199,
1988
89.
Levin, LR,
Han PL,
Hwang PM,
Feinstein PG,
Davis RL,
and
Reed RR.
The Drosophila learning and memory gene rutabaga encodes a Ca2+/calmodulin-responsive adenylyl cyclase.
Cell
68:
479-489,
1992[Web of Science][Medline].
90.
Levin, LR,
and
Reed RR.
Identification of functional domains of adenylyl cyclase using in vivo chimeras.
J Biol Chem
270:
7573-7579,
1995
91.
Levy-Toledano, R,
Blaettler DH,
LaRochelle WJ,
and
Taylor SI.
Insulin-induced activation of phosphatidylinositol (PI) 3-kinase. Insulin-induced phosphorylation of insulin receptors and insulin receptor substrate-1 displaces phosphorylated platelet-derived growth factor receptors from binding sites on PI 3-kinase.
J Biol Chem
270:
30018-30022,
1995
91a.
Lipskaia, L,
Defer N,
Esposito G,
Hajar I,
Garel MC,
Rockman HA,
and
Hanoune J.
Enhanced cardiac function in transgenic mice expressing a Ca(2+)-stimulated adenylyl cyclase.
Circ Res
86:
795-801,
2000
92.
Lipskaia, L,
Djiane A,
Defer N,
and
Hanoune J.
Different expression of adenylyl cyclase isoforms after retinoic acid induction of P19 teratocarcinoma cells.
FEBS Lett
415:
275-280,
1997[Web of Science][Medline].
93.
Lipskaia, L,
Grepin C,
Defer N,
and
Hanoune J.
Adenylyl cyclase activity and gene expression during mesodermal differentiation of the P19 embryonal carcinoma cells.
J Cell Physiol
176:
50-56,
1998[Web of Science][Medline].
94.
Livingstone, MS,
Sziber PP,
and
Quinn WG.
Loss of calcium/calmodulin responsiveness in adenylate cyclase of rutabaga, a Drosophila learning mutant.
Cell
37:
205-215,
1984[Web of Science][Medline].
95.
Lustig, KD,
Conklin BR,
Herzmark P,
Taussig R,
and
Bourne HR.
Type II adenylyl cyclase integrates coincident signals from Gs, Gi, and Gq.
J Biol Chem
268:
13900-13905,
1993
96.
Ma, H,
and
Ling BN.
Luminal adenosine receptors regulate amiloride-sensitive Na+ channels in A6 distal nephron cells.
Am J Physiol Renal Fluid Electrolyte Physiol
270:
F798-F805,
1996
97.
Magnaldo, I,
Pouyssegur J,
and
Paris S.
Cyclic AMP inhibits mitogen-induced DNA synthesis in hamster fibroblasts, regardless of the signalling pathway involved.
FEBS Lett
245:
65-69,
1989[Web of Science][Medline].
98.
Maldonado, R,
Blendy JA,
Tzavara E,
Gass P,
Roques BP,
Hanoune J,
and
Schutz G.
Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB.
Science
273:
657-659,
1996[Abstract].
99.
Maltier, JP,
Bengham-Eyéné Y,
and
Legrand C.
Regulation of myometrial
2-adrenergic receptors by progesterone and estradiol-17
in late pregnant rat.
Biol Reprod
40:
531-540,
1989[Abstract].
100.
Mamluk, R,
Defer N,
Hanoune J,
and
Meidan R.
Molecular identification of adenylyl cyclase 3 in bovine corpus luteum and its regulation by prostaglandin F2
- induced signaling pathway.
Endocrinology
140:
4601-4608,
1999
101.
Marjamaki, A,
Sato M,
Bouet-Alard R,
Yang Q,
Limon-Boulez I,
Legrand C,
and
Lanier SM.
Factors determining the specificity of signal transduction by guanine nucleotide-binding protein-coupled receptors. Integration of stimulatory and inhibitory input to the effector adenylyl cyclase.
J Biol Chem
272:
16466-16473,
1997
102.
Matsuoka, I,
Giuili G,
Poyard M,
Stengel D,
Parma J,
Guellaen G,
and
Hanoune J.
Localization of adenylyl and guanylyl cyclase in rat brain by in situ hybridization: Comparison with calmodulin mRNA distribution.
J Neuroscience
12:
3350-3360,
1992[Abstract].
103.
Matsuoka, I,
Maldonado R,
Defer N,
Noel F,
Hanoune J,
and
Rocques B.
Chronic morphine administration causes region-specific increase of brain type VIII adenylyl cyclase mRNA.
Eur J Pharmacol
268:
215-221,
1994[Web of Science][Medline].
104.
Matsuoka, I,
Suzuki Y,
Defer N,
Nakashini H,
and
Hanoune J.
Differential expression of type I, II, and V adenylyl cyclase gene in the postnatal developing rat brain.
J Neurochem
68:
498-506,
1997[Web of Science][Medline].
105.
Matthes, HW,
Maldonado R,
Simonin F,
Valverde O,
Slowe S,
Kitchen I,
Befort K,
Dierich A,
Le Meur M,
Dolle P,
Tzavara E,
Hanoune J,
Roques BP,
and
Kieffer BL.
Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene.
Nature
383:
819-823,
1996[Medline].
106.
McBurney, MW,
Jones-Villeneuve EMV,
Edwards MKS,
and
Anderson PJ.
Controlled differentiation and maturation of teratocarcinoma cells in culture.
Nature
299:
165-167,
1982[Medline].
107.
Menco, BPM,
Bruch RC,
Dau B,
and
Danho W.
Ultrastructural localization of olfactory transduction components: the G protein subunit Golf and type III adenylyl cyclase.
Neuron
8:
441-453,
1992[Web of Science][Medline].
108.
Mhaouty, S,
Cohen-Tannoudji J,
Bouet-Alard R,
Limon-Boulez I,
Maltier JP,
and
Legrand C.
Characteristics of the
2/
2-adrenergic receptor-coupled adenylyl cyclase system in rat myometrium during pregnancy.
J Biol Chem
270:
11012-11016,
1995
109.
Mhaouty-Kodja, S,
Bouet-Alard R,
Limon-Boulez I,
Maltier JP,
and
Legrand C.
Molecular diversity of adenylyl cyclases in human and rat myometrium. Correlation with global adenylyl cyclase activity during mid- and term pregnancy.
J Biol Chem
272:
31100-31106,
1997
110.
Mons, N,
and
Cooper DM.
Adenylyl cyclase mRNA expression does not reflect the predominant Ca2+/calmodulin-stimulated activity in the hypothalamus.
J Neuroendocrinol
6:
665-671,
1994[Web of Science][Medline].
111.
Mons, N,
and
Cooper DM.
Selective expression of one Ca2+-inhibitable adenylyl cyclase in dopaminergically innervated rat brain regions.
Brain Res Mol Brain Res
22:
236-244,
1994[Medline].
112.
Mons, N,
Harry A,
Dubourg P,
Premont RT,
Iyengar R,
and
Cooper DM.
Immunohistochemical localization of adenylyl cyclase in rat brain indicates a highly selective concentration in synapses.
Proc Natl Acad Sci USA
92:
8473-8477,
1995
113.
Mons, N,
Yoshimura M,
and
Cooper DMF
Discrete expression of Ca2+/calmodulin-sensitive and Ca2+-insensitive adenylyl cyclases in the rat brain.
Synapse
14:
51-59,
1993[Web of Science][Medline].
114.
Moore, MS,
DeZazzo J,
Luk AY,
Tully T,
Singh CM,
and
Heberlein U.
Ethanol intoxication in Drosophila: genetic and pharmacological evidence for regulation by the cAMP signaling pathway.
Cell
93:
997-1007,
1998[Web of Science][Medline].
115.
Muglia, LM,
Schaefer ML,
Vogt SK,
Gurtner G,
Imamura A,
and
Muglia LJ.
The 5'-flanking region of the mouse adenylyl cyclase type VIII gene imparts tissue-specific expression in transgenic mice.
J Neurosci
19:
2051-2058,
1999
116.
Murthy, KS,
and
Makhlouf GM.
Regulation of adenylyl cyclase type V/VI in smooth muscle: interplay of inhibitory G protein and Ca2+ influx.
Mol Pharmacol
54:
122-128,
1998
117.
Nair, BG,
and
Patel TB.
Regulation of cardiac adenylyl cyclase by epidermal growth factor (EGF). Role of EGF receptor protein tyrosine kinase activity.
Biochem Pharmacol
46:
1239-1245,
1993[Web of Science][Medline].
118.
Nair, BG,
Rashed HM,
and
Patel TB.
Epidermal growth factor produces inotropic and chronotropic effects in rat hearts by increasing cyclic AMP accumulation.
Growth Factors
8:
41-48,
1993[Web of Science][Medline].
119.
Nair, BG,
Rashed HM,
and
Patel TB.
Epidermal growth factor stimulates rat cardiac adenylate cyclase through a GTP-binding regulatory protein.
Biochem J
264:
563-571,
1989[Web of Science][Medline].
120.
Nakanishi, H,
Brewer KA,
and
Exton JH.
Activation of the
isozyme of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate.
J Biol Chem
268:
13-16,
1993
121.
Neer, E.
Physical and functional properties of adenylate cyclase from mature rat testis.
J Biol Chem
253:
5808-5812,
1978
122.
Nestler, EJ.
Molecular mechanisms of drug addiction.
J Neurosci
12:
2439-2450,
1992[Web of Science][Medline].
123.
Okusa, MD,
Huang L,
Momose-Hotokezaka A,
Huynh LP,
and
Mangrum AJ.
Regulation of adenylyl cyclase in polarized renal epithelial cells by G protein-coupled receptors.
Am J Physiol Renal Physiol
273:
F883-F891,
1997
124.
Olianas, MC,
and
Onali P.
GABA(B) receptor-mediated stimulation of adenylyl cyclase activity in membranes of rat olfactory bulb.
Br J Pharmacol
126:
657-664,
1999[Web of Science][Medline].
125.
Olianas, MC,
and
Onali P.
Mediation by G protein 
subunits of the opioid stimulation of adenylyl cyclase activity in rat olfactory bulb.
Biochem Pharmacol
57:
649-652,
1999[Web of Science][Medline].
126.
Otte, AP,
van Run P,
Heideveld M,
van Driel R,
and
Durston AJ.
Neural induction is mediated by cross-talk between the protein kinase C and cyclic AMP pathways.
Cell
58:
641-648,
1989[Web of Science][Medline].
127.
Parsian, A,
Todd RD,
Cloninger CR,
Hoffman PL,
Ovchinnikova L,
Ikeda H,
and
Tabakoff B.
Platelet adenylyl cyclase activity in alcoholics and subtypes of alcoholics. WHO/ISBRA Study Clin Centers Alcohol
Clin Exp Res
20:
745-751,
1996.
128.
Paterson, JM,
Smith SM,
Harmar AJ,
and
Antoni FA.
Control of a novel adenylyl cyclase by calcineurin.
Biochem Biophys Res Commun
214:
1000-1008,
1995[Web of Science][Medline].
129.
Pieroni, JP,
Harry A,
Chen J,
Jacobowitz O,
Magnusson RP,
and
Iyengar R.
Distinct characteristics of the basal activities of adenylyl cyclases 2 and 6.
J Biol Chem
270:
21368-21373,
1995
130.
Pitt, GS,
Milona N,
Borleis J,
Lin KC,
Reed RR,
and
Devreotes PN.
Structurally distinct and stage-specific adenylyl cyclase genes play different roles in Dictyostelium development.
Cell
69:
305-315,
1992[Web of Science][Medline].
131.
Post, SR,
Hilal-Dandan R,
Urasawa K,
Brunton LL,
and
Insel PA.
Quantification of signalling components and amplification in the
-adrenergic-receptor-adenylate cyclase pathway in isolated adult rat ventricular myocytes.
Biochem J
311:
75-80,
1995.
132.
Premont, RT,
Chen J,
Ma-W H,
Ponnapalli M,
and
Iyengar R.
Two members of a widely expressed subfamily of hormone-stimulated adenylyl cyclases.
Proc Natl Acad Sci USA
89:
9809-9813,
1992
133.
Premont, RT,
Jacobowitz O,
and
Iyengar R.
Lowered responsiveness of the catalyst of adenylyl cyclase to stimulation by Gs in heterologous desensitization: a role for adenosine 3', 5'-monophosphate-dependent phosphorylation.
Endocrinology
131:
2774-2784,
1992
134.
Premont, RT,
Matsuoka I,
Mattei MG,
Pouille Y,
Defer N,
and
Hanoune J.
Identification and characterization of a novel and widely-expressed isoform of adenylyl cyclase.
J Biol Chem
271:
13900-13907,
1996
135.
Puceat, M,
Bony C,
Jaconi M,
and
Vassort G.
Specific activation of adenylyl cyclase V by a purinergic agonist.
FEBS Lett
431:
189-194,
1998[Web of Science][Medline].
136.
Rabbani, M,
Nelson EJ,
Hoffman PL,
and
Tabakoff B.
Role of protein kinase C in ethanol-induced activation of adenylyl cyclase.
Alcohol Clin Exp Res
23:
77-86,
1999[Web of Science][Medline].
137.
Ratsma, JE,
Gunning WB,
Leurs R,
and
Schoffelmeer AN.
Platelet adenylyl cyclase activity as a biochemical trait marker for predisposition to alcoholism.
Alcohol Clin Exp Res
23:
600-4,
1999[Web of Science][Medline].
138.
Rodbell Nobel Lecture M..
Signal transduction: evolution of an idea.
Biosci Rep
15:
117-33,
1995[Web of Science][Medline].
139.
Scholich, K,
Barbier AJ,
Mullenix JB,
and
Patel TB.
Characterization of soluble forms of nonchimeric type V adenylyl cyclases.
Proc Natl Acad Sci USA
94:
2915-2920,
1997
140.
Schwencke, C,
Yamamoto M,
Okumura S,
Toya Y,
Kim SJ,
and
Ishikawa Y.
Compartmentation of cyclic adenosine 3',5'-monophosphate signaling in caveolae.
Mol Endocrinol
13:
1061-1070,
1999
141.
Sharma, SK,
Klee WA,
and
Nirenberg M.
Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance.
Proc Natl Acad Sci USA
74:
3365-3369,
1975.
142.
Shen, T,
Suzuki Y,
Poyard M,
Best-Belpomme M,
Defer N,
and
Hanoune J.
Localization and differential expression of adenylyl cyclase messenger ribonucleic acids in rat adrenal gland determined by in situ hybridization.
Endocrinology
138:
4591-4598,
1997
143.
Shen, T,
Suzuki Y,
Poyard M,
Miyamoto N,
Defer N,
and
Hanoune J.
Expression of adenylyl cyclase mRNAs in the adult, in developing, and in the Brattleboro rat kidney.
Am J Physiol Cell Physiol
273:
C323-C330,
1997
144.
Shlatz, LJ,
Schwartz IL,
Kinne-Saffran E,
and
Kinne R.
Distribution of parathyroid hormone-stimulated adenylate cyclase in plasma membranes of cells of the kidney cortex.
J Membr Biol
24:
131-144,
1975[Web of Science][Medline].
145.
Simonds, WF.
G protein regulation of adenylate cyclase.
Trends Pharmacol Sci
20:
66-73,
1999[Medline].
146.
Smit, MJ,
and
Iyengar R.
Mammalian adenylyl cyclases.
Adv Second Messenger Phosphoprotein Res
32:
1-21,
1998[Medline].
147.
Smit, MJ,
Verzijl D,
and
Iyengar R.
Identity of adenylyl cyclase isoform determines the rate of cell cycle progression in NIH 3T3 cells.
Proc Natl Acad Sci USA
95:
15084-15089,
1998
148.
Stengel, D,
and
Hanoune J.
The catalytic subunit of ram sperm adenylate cyclase can be activated through the guanine nucleotide regulatory component and prostaglandin receptors of human erythrocyte.
J Biol Chem
256:
5394-5398,
1981
149.
Stengel, D,
Henry D,
Tomova S,
Borsodi A,
and
Hanoune J.
Purification of the proteolytically solubilized, active catalytic subunit of adenylate cyclase from ram sperm. Inhibition by adenosine.
Eur J Biochem
161:
241-247,
1986[Web of Science][Medline].
150.
Stengel, D,
Parma J,
Gannage-H M,
Roeckel N,
Mattei M-G,
Barouki R,
and
Hanoune J.
Different chromosomal localization of two adenylyl cyclase genes expressed in human brain.
Hum Genet
90:
126-130,
1992[Web of Science][Medline].
151.
Storm, DR,
Hansel C,
Hacker B,
Parent A,
and
Linden DJ.
Impaired cerebellar long-term potentiation in type I adenylyl cyclase mutant mice.
Neuron
20:
1199-210,
1998[Web of Science][Medline].
152.
Sunahara, RK,
Dessauer CW,
and
Gilman AG.
Complexity and diversity of mammalian adenylyl cyclases.
Annu Rev Pharmacol Toxicol
36:
461-480,
1996[Web of Science][Medline].
153.
Suzuki, Y,
Shen T,
Miyamoto N,
Defer N,
Matsuoka I,
and
Hanoune J.
Changes in the expression of adenylyl cyclases in the rat uterus during the course of pregnancy.
Biol Reprod
57:
778-782,
1997[Abstract].
154.
Suzuki, Y,
Shen T,
Poyard M,
Best-Belpomme M,
Hanoune J,
and
Defer N.
Expression of adenylyl cyclase mRNAs in the denervated and in the developing mouse skeletal muscle.
Am J Physiol Cell Physiol
274:
C1674-C1685,
1998
155.
Takaichi, K,
and
Kurokawa K.
High Ca2+ inhibits peptide hormone-dependent cAMP production specifically in thick ascending limbs of Henle.
Miner Electrolyte Metab
12:
342-346,
1986[Web of Science][Medline].
156.
Tang, W-J,
and
Gilman AG.
Type-specific regulation of adenylyl cyclase by G protein 
-subunits.
Science
254:
1500-1503,
1991
157.
Tang, W-J,
and
Gilman AG.
Construction of a soluble adenylyl cyclase activated by Gs
and forskolin.
Science
268:
1769-1772,
1995
158.
Tang, W-J,
and
Hurley JH.
Catalytic mechanism and regulation of mammalian adenylyl cyclases.
Mol Pharmacol
54:
231-240,
1998
159.
Tang, W-J,
Krupinski J,
and
Gilman AG.
Expression and characterization of calmodulin-activated (type I) adenylylcyclase.
J Biol Chem
266:
8595-8603,
1991
160.
Taussig, R,
and
Gilman AG.
Mammalian membrane-bound adenylyl cyclases.
J Biol Chem
270:
1-4,
1995
161.
Taussig, R,
Iniguez-Lluhi JA,
and
Gilman AG.
Inhibition of adenylyl cyclase by Gi
.
Science
261:
218-221,
1993
162.
Taussig, R,
Quarmby LM,
and
Gilman AG.
Regulation of purified type I and type II adenylyl cyclases by G protein 
subunits.
J Biol Chem
268:
9-12,
1993
163.
Taussig, R,
Tang WJ,
Hepler JR,
and
Gilman AG.
Distinct patterns of bidirectional regulation of mammalian adenylyl cyclases.
J Biol Chem
269:
6093-6100,
1994
164.
Terwilliger, RZ,
Beitner-Johnson D,
Sevarino KA,
Crain SM,
and
Nestler EJ.
A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function.
Brain Res
548:
100-110,
1991[Web of Science][Medline].
165.
Tesmer, JJ,
and
Sprang SR.
The structure, catalytic mechanism and regulation of adenylyl cyclase.
Curr Opin Struct Biol
8:
713-719,
1998[Web of Science][Medline].
166.
Tesmer, JJ,
Sunahara RK,
Gilman AG,
and
Sprang SR.
Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gs
-GTP
S.
Science
278:
1907-1916,
1997
167.
Thomas, JM,
and
Hoffman BB.
Adenylate cyclase supersensitivity: a general means of cellular adaptation to inhibitory agonists?
Trends Pharmacol Sci
8:
308-311,
1987.
168.
Thomas, JM,
and
Hoffman BB.
Isoform-specific sensitization of adenylyl cyclase activity by prior activation of inhibitory receptors: role of 
subunits in transducing enhanced activity of the type VI isoform.
Mol Pharmacol
49:
907-914,
1996[Abstract].
169.
Tobise, K,
Ishikawa Y,
Holmer SR,
Im-J M,
Newell JB,
Yoshie H,
Fujita M,
Susannie EE,
and
Homcy CJ.
Changes in type VI adenylyl cyclase isoform expression correlate with a decreased capacity for cAMP generation in the aging ventricle.
Circ Res
74:
596-603,
1994
170.
Tzavara, ET,
Pouille Y,
Defer N,
and
Hanoune J.
Diurnal variation of the adenylyl cyclase type 1 in the rat pineal gland.
Proc Natl Acad Sci USA
93:
11208-11212,
1996
171.
Villacres, EC,
Wong ST,
Chavkin C,
and
Storm DR.
Type I adenylyl cyclase mutant mice have impaired mossy fiber long-term potentiation.
J Neurosci
18:
3186-3194,
1998
172.
Villacres, EC,
Wu Z,
Hua W,
Nielsen MD,
Watters JJ,
Yan C,
Beavo J,
and
Storm DR.
Developmentally expressed Ca(2+)-sensitive adenylyl cyclase activity is disrupted in the brains of type I adenylyl cyclase mutant mice.
J Biol Chem
270:
14352-14357,
1995
173.
Villacres, EC,
Xia Z,
Bookbinder LH,
Edelhoff S,
Disteche CM,
and
Storm DR.
Cloning, chromosomal mapping, and expression of human fetal brain type I adenylyl cyclase.
Genomics
16:
473-478,
1993[Web of Science][Medline].
174.
Vivat, V,
Cohen-Tannoudji J,
Revelli JP,
Muzzin P,
Giacobino JP,
Maltier JP,
and
Legrand C.
Progesterone transcriptionally regulates the
2-adrenergic receptor gene in pregnant rat myometrium.
J Biol Chem
267:
7975-7978,
1992
175.
Vorherr, T,
Knopfel L,
Hofmann F,
Mollner S,
Pfeuffer T,
and
Carafoli E.
The calmodulin binding domain of nitric oxide synthase and adenylyl cyclase.
Biochemistry
32:
6081-6088,
1993[Medline].
176.
Vossler, MR,
Yao H,
York RD,
Pan MG,
Rim CS,
and
Stork PJ.
cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway.
Cell
89:
73-82,
1997[Web of Science][Medline].
177.
Wang, L,
and
Gintzler AR.
Bimodal opioid regulation of cyclic AMP formation: implications for positive and negative coupling of opiate receptors to adenylyl cyclase.
J Neurochem
63:
1726-1730,
1994[Web of Science][Medline].
178.
Wang, MM,
Tsai RYL,
Schrader KA,
and
Reed RR.
Genes encoding components of the olfactory signal transduction cascade contain a DNA binding site that may direct neuronal expression.
Mol Cell Biol
13:
5805-5813,
1993
179.
Watson, PA,
Krupinski J,
Kempinski AM,
and
Frankenfield CD.
Molecular cloning and characterization of the type VII isoform of mammalian adenylyl cyclase expressed widely in mouse tissues and in S49 mouse lymphoma cells.
J Biol Chem
269:
28893-28898,
1994
180.
Wayman, GA,
Wei J,
Wong S,
and
Storm DR.
Regulation of type I adenylyl cyclase by calmodulin kinase IV in vivo.
Mol Cell Biol
16:
6075-6082,
1996[Abstract].
181.
Wei, J,
Wayman G,
and
Storm DR.
Phosphorylation and inhibition of type III adenylyl cyclase by calmodulin-dependent protein kinase II in vivo.
J Biol Chem
271:
24231-24235,
1996
182.
Welker, E,
Armstrong-James M,
Bronchti G,
Ourednik W,
Gheorghita-Baechler F,
Dubois R,
Guernsey DL,
Van der Loos H,
and
Neumann PE.
Altered sensory processing in the somatosensory cortex of the mouse mutant barrelless.
Science
271:
1864-1867,
1996[Abstract].
183.
Whisnant, RE,
Gilman AG,
and
Dessauer CW.
Interaction of the two cytosolic domains of mammalian adenylyl cyclase.
Proc Natl Acad Sci USA
93:
6621-6625,
1996
184.
Wu, J,
Dent P,
Jelinek T,
Wolfman A,
Weber MJ,
and
Sturgill TW.
Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate.
Science
262:
1065-1069,
1993
185.
Wu, Z,
Wong ST,
and
Storm DR.
Modification of the calcium and calmodulin sensitivity of the type I adenylyl cyclase by mutagenesis of its calmodulin binding domain.
J Biol Chem
268:
23766-23768,
1993
186.
Wu, ZL,
Thomas SA,
Villacres EC,
Xia Z,
Simmons ML,
Chavkin C,
Palmiter RD,
and
Storm DR.
Altered behavior and long-term potentiation in type I adenylyl cyclase mutant mice.
Proc Natl Acad Sci USA
92:
220-224,
1995
187.
Xia, Z,
Choi E-J,
Wang F,
Blazynski C,
and
Storm DR.
Type I calmodulin-sensitive adenylyl cyclase is neural specific.
J Neurochem
60:
305-311,
1993[Web of Science][Medline].
188.
Xia, Z,
Choi E-J,
Wang F,
and
Storm DR.
The type III calcium/calmodulin-sensitive adenylyl cyclase is not specific of olfactory neurons.
Neurosci Lett
144:
169-173,
1992[Web of Science][Medline].
189.
Xia, Z,
Refsdal CD,
Merchant DM,
Dorsa DM,
and
Storm DE.
Distribution of mRNA for the calmodulin-sensitive adenylate cyclase in rat brain: expression in areas associated with learning and memory.
Neuron
6:
431-443,
1991[Web of Science][Medline].
190.
Xia, Z,
and
Storm DR.
Calmodulin-regulated adenylyl cyclases and neuromodulation.
Curr Opin Neurobiol
7:
391-396,
1997[Web of Science][Medline].
191.
Yan, SZ,
Hahn D,
Huang ZH,
and
Tang WJ.
Two cytoplasmic domains of mammalian adenylyl cyclase form a Gs
- and forskolin-activated enzyme in vitro.
J Biol Chem
271:
10941-10945,
1996
192.
Yan, SZ,
Huang ZH,
Andrews RK,
and
Tang WJ.
Conversion of forskolin-insensitive to forskolin-sensitive (mouse-type IX) adenylyl cyclase.
Mol Pharmacol
53:
182-187,
1998
193.
Yang, B,
He B,
Abdel-Halim SM,
Tibell A,
Brendel MD,
Bretzel RG,
Efendic S,
and
Hillert J.
Molecular cloning of a full-length cDNA for human type 3 adenylyl cyclase and its expression in human islets.
Biochem Biophys Res Commun
254:
548-551,
1999[Web of Science][Medline].
194.
Yoshimura, M,
and
Cooper DM.
Type-specific stimulation of adenylylcyclase by protein kinase C.
J Biol Chem
268:
4604-4607,
1993
195.
Yoshimura, M,
and
Cooper DMF
Cloning and expression of Ca2+-inhibitable adenylyl cyclase from NCB-20 cells.
Proc Natl Acad Sci USA
89:
6716-6720,
1992
196.
Yoshimura, M,
Ikeda H,
and
Tabakoff B.
µ-Opioid receptors inhibit dopamine-stimulated activity of type V adenylyl cyclase but enhance dopamine-stimulated activity of type VII adenylyl cyclase.
Mol Pharmacol
50:
43-51,
1996[Abstract].
197.
Yoshimura, M,
and
Tabakoff B.
Selective effects of ethanol on the generation of cAMP by particular members of the adenylyl cyclase family.
Alcohol Clin Exp Res
19:
1435-1440,
1995[Web of Science][Medline].
198.
Yu, HJ,
Unnerstall JR,
and
Green RD.
Determination and cellular localisation of adenylyl cyclase isoenzymes expressed in embryonic chick heart.
FEBS Lett
374:
89-94,
1995[Web of Science][Medline].
199.
Yung, LY,
Tsim ST,
and
Wong YH.
Stimulation of cAMP accumulation by the cloned Xenopus melatonin receptor through Gi and Gz proteins.
FEBS Lett
372:
99-102,
1995[Web of Science][Medline].
200.
Zhang, G,
Liu Y,
Ruoho AE,
and
Hurley JH.
Structure of the adenylyl cyclase catalytic core.
Nature
386:
247-253,
1997[Medline].
201.
Zimmermann, G,
and
Taussig R.
Protein kinase C alters the responsiveness of adenylyl cyclases to G protein
and 
subunits.
J Biol Chem
271:
27161-27166,
1996
This article has been cited by other articles:
![]() |
M. Gottle, J. Geduhn, B. Konig, A. Gille, K. Hocherl, and R. Seifert Characterization of Mouse Heart Adenylyl Cyclase J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 1156 - 1165. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhao, A. Jones, K. R. Olson, K. Peng, T. Wehrman, A. Park, R. Mallari, D. Nebalasca, S. W. Young, and S.-H. Xiao A Homogeneous Enzyme Fragment Complementation-Based {beta}-Arrestin Translocation Assay for High-Throughput Screening of G-Protein-Coupled Receptors J Biomol Screen, September 1, 2008; 13(8): 737 - 747. [Abstract] [PDF] |
||||
![]() |
L. E. Vinge, P. W. Raake, and W. J. Koch Gene Therapy in Heart Failure Circ. Res., June 20, 2008; 102(12): 1458 - 1470. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Gros, S. Van Uum, A. Hutchinson-Jaffe, Q. Ding, J. G. Pickering, R. A. Hegele, and R. D. Feldman Increased Enzyme Activity and -Adrenergic Mediated Vasodilation in Subjects Expressing a Single-Nucleotide Variant of Human Adenylyl Cyclase 6 Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2657 - 2663. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Chester and V. J. Watts Adenylyl Cyclase 5: A New Clue in the Search for the "Fountain of Youth"? Sci. Signal., November 20, 2007; 2007(413): pe64 - pe64. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Sabbatini, M. Rodriguez, M. B. di Carlo, C. A. Davio, M. S. Vatta, and L. G. Bianciotti C-type natriuretic peptide enhances amylase release through NPR-C receptors in the exocrine pancreas Am J Physiol Gastrointest Liver Physiol, November 1, 2007; 293(5): G987 - G994. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. J. Watts Adenylyl Cyclase Isoforms as Novel Therapeutic Targets: An Exciting Example of Excitotoxicity Neuroprotection Mol. Interv., April 1, 2007; 7(2): 70 - 73. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Ortiz-Capisano, P. A. Ortiz, P. Harding, J. L. Garvin, and W. H. Beierwaltes Adenylyl Cyclase Isoform V Mediates Renin Release From Juxtaglomerular Cells Hypertension, March 1, 2007; 49(3): 618 - 624. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-H. Han, U-Y. Lee, Y.-S. Jang, Y. M. Cho, Y. M. Jang, I.-A Hwang, J. Y. Ghee, S.-W. Lim, W.-Y. Kim, C. W. Yang, et al. Differential regulation of B/K protein expression in proximal and distal tubules of rat kidneys with ischemia-reperfusion injury Am J Physiol Renal Physiol, January 1, 2007; 292(1): F100 - F106. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Ortiz-Capisano, P. A. Ortiz, P. Harding, J. L. Garvin, and W. H. Beierwaltes Decreased Intracellular Calcium Stimulates Renin Release via Calcium-Inhibitable Adenylyl Cyclase Hypertension, January 1, 2007; 49(1): 162 - 169. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Grunberger, B. Obermayer, J. Klar, A. Kurtz, and F. Schweda The Calcium Paradoxon of Renin Release: Calcium Suppresses Renin Exocytosis by Inhibition of Calcium-Dependent Adenylate Cyclases AC5 and AC6 Circ. Res., November 24, 2006; 99(11): 1197 - 1206. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Fischmeister, L. R.V. Castro, A. Abi-Gerges, F. Rochais, J. Jurevicius, J. Leroy, and G. Vandecasteele Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases Circ. Res., October 13, 2006; 99(8): 816 - 828. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yamada, T. Inagaki, R. Funahashi, Y. Yoshimura, and Y. Komatsu High-Frequency Stimulation Together with Adrenoceptor Activation Facilitates the Maintenance of Long-Term Potentiation at Visual Cortical Inhibitory Synapses Cereb Cortex, September 1, 2006; 16(9): 1239 - 1248. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Leineweber, M. Bohm, and G. Heusch Cyclic Adenosine Monophosphate in Acute Myocardial Infarction With Heart Failure: Slayer or Savior? Circulation, August 1, 2006; 114(5): 365 - 367. [Full Text] [PDF] |
||||
![]() |
R. F. Watson, R. M. Abdel-Majid, M. W. Barnett, B. S. Willis, A. Katsnelson, T. H. Gillingwater, G. S. McKnight, P. C. Kind, and P. E. Neumann Involvement of protein kinase A in patterning of the mouse somatosensory cortex. J. Neurosci., May 17, 2006; 26(20): 5393 - 5401. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. Fraser, E. Beyret, S. R. Milligan, and S. A. Adeoya-Osiguwa Effects of estrogenic xenobiotics on human and mouse spermatozoa Hum. Reprod., May 1, 2006; 21(5): 1184 - 1193. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Dahle, A. E. Myhre, A. O. Aasen, and J. E. Wang Effects of Forskolin on Kupffer Cell Production of Interleukin-10 and Tumor Necrosis Factor Alpha Differ from Those of Endogenous Adenylyl Cyclase Activators: Possible Role for Adenylyl Cyclase 9 Infect. Immun., November 1, 2005; 73(11): 7290 - 7296. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Matsumoto, T. Kobayashi, K. Wakabayashi, and K. Kamata Cilostazol improves endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from diabetic rats Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1933 - H1940. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Matsumoto, K. Wakabayashi, T. Kobayashi, and K. Kamata Functional changes in adenylyl cyclases and associated decreases in relaxation responses in mesenteric arteries from diabetic rats Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2234 - H2243. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Seino and T. Shibasaki PKA-Dependent and PKA-Independent Pathways for cAMP-Regulated Exocytosis Physiol Rev, October 1, 2005; 85(4): 1303 - 1342. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Pullar and R. R. Isseroff Cyclic AMP mediates keratinocyte directional migration in an electric field J. Cell Sci., May 1, 2005; 118(9): 2023 - 2034. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mededovic and L. R Fraser Mechanisms of action of angiotensin II on mammalian sperm function Reproduction, February 1, 2005; 129(2): 211 - 218. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Bailey Inhibition of bicarbonate reabsorption in the rat proximal tubule by activation of luminal P2Y1 receptors Am J Physiol Renal Physiol, October 1, 2004; 287(4): F789 - F796. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sobolewski, K. B. Jourdan, P. D. Upton, L. Long, and N. W. Morrell Mechanism of cicaprost-induced desensitization in rat pulmonary artery smooth muscle cells involves a PKA-mediated inhibition of adenylyl cyclase Am J Physiol Lung Cell Mol Physiol, August 1, 2004; 287(2): L352 - L359. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mededovic and L. R Fraser Angiotensin II stimulates cAMP production and protein tyrosine phosphorylation in mouse spermatozoa Reproduction, May 1, 2004; 127(5): 601 - 612. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. Fraser, S. A. Adeoya-Osiguwa, and R. W. Baxendale First messenger regulation of capacitation via G protein-coupled mechanisms: a tale of serendipity and discovery Mol. Hum. Reprod., December 1, 2003; 9(12): 739 - 748. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. GEORGET, P. MATEO, G. VANDECASTEELE, L. LIPSKAIA, N. DEFER, J. HANOUNE, J. HOERTER, C. LUGNIER, and R. FISCHMEISTER Cyclic AMP compartmentation due to increased cAMP-phosphodiesterase activity in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8) FASEB J, August 1, 2003; 17(11): 1380 - 1391. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Di Sole, R. Cerull, S. Petzke, V. Casavola, G. Burckhardt, and C. Helmle-Kolb Bimodal Acute Effects of A1 Adenosine Receptor Activation on Na+/H+ Exchanger 3 in Opossum Kidney Cells J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1720 - 1730. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Chignard, M. Mergey, D. Veissiere, R. Poupon, J. Capeau, R. Parc, A. Paul, and C. Housset Bile salts potentiate adenylyl cyclase activity and cAMP-regulated secretion in human gallbladder epithelium Am J Physiol Gastrointest Liver Physiol, February 1, 2003; 284(2): G205 - G212. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Gustafsson and L. L. Brunton Attenuation of cAMP accumulation in adult rat cardiac fibroblasts by IL-1beta and NO: role of cGMP-stimulated PDE2 Am J Physiol Cell Physiol, August 1, 2002; 283(2): C463 - C471. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Feldman Adenylyl Cyclase: A New Target for Heart Failure Therapeutics Circulation, April 23, 2002; 105(16): 1876 - 1878. [Full Text] [PDF] |
||||
![]() |
K. Scholich, S. Pierre, and T. B. Patel Protein Associated with Myc (PAM) Is a Potent Inhibitor of Adenylyl Cyclases J. Biol. Chem., December 7, 2001; 276(50): 47583 - 47589. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hatakeyama, O. Kozawa, M. Niwa, H. Matsuno, K. Kato, N. Tatematsu, T. Shibata, and T. Uematsu Inhibition by adenylyl cyclase-cAMP system of ET-1-induced HSP27 in osteoblasts Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1260 - E1266. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E Belevych, C. Sims, and R. D Harvey ACh-induced rebound stimulation of L-type Ca2+ current in guinea-pig ventricular myocytes, mediated by G{beta}{gamma}-dependent activation of adenylyl cyclase J. Physiol., November 1, 2001; 536(3): 677 - 692. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tian and S. G. Laychock Protein Kinase C and Calcium Regulation of Adenylyl Cyclase in Isolated Rat Pancreatic Islets Diabetes, November 1, 2001; 50(11): 2505 - 2513. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mizuhashi, N. Nishiyama, N. Matsuki, and Y. Ikegaya Cyclic Nucleotide-Mediated Regulation of Hippocampal Mossy Fiber Development: A Target-Specific Guidance J. Neurosci., August 15, 2001; 21(16): 6181 - 6194. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. J. Evans, J. D. Cropper, K. A. Berg, and W. P. Clarke Mechanisms of Regulation of Agonist Efficacy at the 5-HT1A Receptor by Phospholipid-Derived Signaling Components J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 1025 - 1035. [Abstract] [Full Text] |
||||
![]() |
W. E. McIntire, G. MacCleery, and J. C. Garrison The G Protein beta Subunit Is a Determinant in the Coupling of Gs to the beta 1-Adrenergic and A2a Adenosine Receptors J. Biol. Chem., May 4, 2001; 276(19): 15801 - 15809. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Morel, I. Dublineau, F. Lebrun, and N. M. Griffiths Alterations of the VIP-stimulated cAMP pathway in rat distal colon after abdominal irradiation Am J Physiol Gastrointest Liver Physiol, May 1, 2002; 282(5): G835 - G843. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |